Astrazeneca PLC 6-K, filed Jul 30, 2020
Astrazeneca PLC (AZN)
6-K
2020-07-30
For: 2020-07-30
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on July 30, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July
2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AZN: H1 2020
results
AstraZeneca PLC
30 July
2020 07:00 BST
H1 2020 results
A strong performance during the pandemic; a leader in the fight
against COVID-19
During
the COVID-19 global pandemic, AstraZeneca’s priority was and
will continue to be the safe supply of medicines to millions of
patients. In the first half, revenue, profit and cash-flow
continued to grow. This performance was supported by successful
launches of new medicines1 and more encouraging
progress from the pipeline. The Company’s focus on growth
through innovation is designed to support a continuation of these
trends.
Pascal Soriot, Chief Executive Officer, commented:
“I
want to thank my colleagues around the world for producing a strong
performance in the first half of the year, delivering further
revenue growth and another step forward in profitability and cash
generation. I was particularly pleased with the robust growth in
Emerging Markets and the success of our new medicines. We made
further progress with our pipeline, highlighted by the overwhelming
success of Tagrisso in the
ADAURA trial and with Farxiga, which expanded its potential
beyond diabetes. We are also pleased with our new collaboration
with Daiichi Sankyo on DS-1062, which strengthens our growing
Oncology portfolio.
Furthermore,
our company has mounted a significant response to COVID-19, with
capacity to deliver over two billion doses of AZD1222, the
accelerated development of our monoclonal antibodies and new trials
for the use of Calquence
and Farxiga to treat
patients affected by the virus.
Looking
ahead, while we continue to anticipate variations in quarterly
performance, the continuation of our strategy makes us confident
about the future. We are retaining our full-year guidance that is
underpinned by the focus on commercial execution and an exciting
pipeline of new medicines.”
Financial performance
|
|
H1 2020
|
Q2 2020
|
||||
|
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER2
|
Actual
|
CER
|
|||
|
Total Revenue
|
12,629
|
12
|
14
|
6,275
|
8
|
11
|
|
Product Sales
|
12,359
|
11
|
13
|
6,048
|
6
|
9
|
|
Collaboration Revenue
|
270
|
n/m3
|
n/m
|
227
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Reported4
EPS5
|
$1.17
|
n/m
|
n/m
|
$0.58
|
n/m
|
n/m
|
|
Core6
EPS
|
$2.01
|
24
|
26
|
$0.96
|
32
|
31
|
There
was only a modest inventory-related benefit to Total Revenue,
reflecting the effects of the ongoing COVID-19 pandemic, in the
first half of the year.
Total
Revenue increased by 12% (14% at CER) to $12,629m in the half, with
growth across all three therapy areas7 and in every region.
Highlights of Total Revenue included:
-
The performance of
the new medicines, which improved by 42% (45% at CER) to $6,353m,
including new-medicine growth in Emerging Markets of 71% (79% at
CER) to $1,406m. These medicines represented 50% of global Total
Revenue (H1 2019: 40%)
-
Growth across all
therapy areas: Oncology +28% (+31% at
CER) to $5,324m, New CVRM8 +8% (+11% at CER) to
$2,265m and Respiratory & Immunology +5% (+7% at CER) to
$2,676m. In the second quarter, Respiratory & Immunology Total
Revenue of $1,122m declined by 11% (8% at CER), reflecting the
adverse impact of COVID-19 on sales of Pulmicort in China
-
Growth in every
region: an increase in Emerging Markets of 9% (15% at CER) to
$4,329m, with China growth of 10% (14% at CER) to $2,659m. China
increased by 7% in the second quarter (12% at CER) to $1,243m.
Total Revenue in the US increased by 13% in the half to $4,177m and
in Europe by 17% (20% at CER) to $2,447m
COVID-19
In
addition to the array of efforts listed in the prior results
announcement, the Company has mobilised research efforts to
find new ways to help target the SARS-CoV-2 virus, reduce the
cytokine storm9 and limit organ
damage; for the latest AstraZeneca communications regarding
COVID-19, please click
here.
AstraZeneca
has prioritised broad and equitable supply of a vaccine throughout
the world at no profit during the pandemic, details of which can be
found in the sustainability section of this document. In July 2020,
results from the ongoing Phase I/II COV001 trial, led by the
University of Oxford, were published in The
Lancet showing that recombinant adenovirus vaccine AZD1222
(ChAdOx1 nCoV-19) was tolerated and generated robust immune
responses against the SARS-CoV-2 virus in evaluated participants.
Late-stage trials are currently underway in the UK, Brazil and
South Africa and are due to start in the US. These trials will
determine how well the vaccine will protect from the COVID-19
disease and measure safety and immune responses in different age
ranges, at various doses.
Further
details of the Company’s broad COVID-19 research and
development programme and agreements to establish manufacturing
capacity are shown later in this announcement.
Guidance
The
Company provides guidance for FY 2020 at CER on:
-
Total Revenue,
comprising Product Sales and Collaboration Revenue
-
Core
EPS
Guidance
partly reflects the changing nature and growing strategic impact of
Collaboration Revenue which, over time, will primarily comprise
potential income from various collaborations,
including:
-
A share of gross
profits derived from sales of Enhertu in several markets, where those
sales are recorded by Daiichi Sankyo Company, Limited (Daiichi
Sankyo)
-
A share of gross
profits derived from sales of roxadustat in China recorded by
FibroGen Inc. (FibroGen)10
-
Milestone revenue
from the MSD11 collaboration on
Lynparza
-
Smaller amounts of
milestone and royalty revenue from other marketed and pipeline
medicines
Financial
guidance for FY 2020 is unchanged. Total Revenue is expected to
increase by a high single-digit to a low double-digit percentage
and Core EPS is expected to increase by a mid- to high-teens
percentage.
AstraZeneca
recognises the heightened risks and uncertainties from the impact
of COVID-19 referred to later in this announcement. Variations in
performance between quarters can be expected to
continue.
The
Company is unable to provide guidance and indications on a Reported
basis because AstraZeneca cannot reliably forecast material
elements of the Reported result, including any fair-value
adjustments arising on acquisition-related liabilities,
intangible-asset impairment charges and legal-settlement
provisions. Please refer to the cautionary-statements section
regarding forward-looking statements at the end of this
announcement.
Indications
The
Company provides indications for FY 2020 at CER:
-
The Company is
focused on improving operating leverage
-
A Core Tax Rate of
18-22%. Variations in the Core Tax Rate between quarters are
anticipated to continue
-
Capital Expenditure
is expected to be broadly stable versus the prior year
Currency impact
If
foreign-exchange rates for July to December 2020 were to remain at
the average of rates seen in the half, it is anticipated that there
would be a low single-digit adverse impact on Total Revenue and
Core EPS. The Company’s foreign-exchange rate sensitivity
analysis is contained within the operating and financial
review.
Financial summary
-
Total Revenue,
comprising Product Sales and Collaboration Revenue, increased by
12% in the half (14% at CER) to $12,629m. Product Sales increased
by 11% (13% at CER) to $12,359m, primarily driven by the
performances of the new medicines within Emerging Markets and
Oncology
-
The Reported and
Core Gross Profit Margins12 were stable at 81%;
the Core Gross Profit Margin declined by one percentage point at
CER, partly reflecting the impact of a one-off change in estimate
relating to Group inventory valuation and the growth in profit
share from the collaboration with MSD in respect of Lynparza. The Core Gross Profit Margin
increased in the second quarter by two percentage points (one at
CER) to 84%, reflecting the mix of Product Sales and manufacturing
efficiencies
-
Reported Total
Operating Expense increased by 1% in the half (3% at CER) to
$8,322m and represented 66% of Total Revenue (H1 2019: 73%). Core
Total Operating Expense increased by 5% (7% at CER) to $7,256m and
represented 57% of Total Revenue (H1 2019: 61%). The increases
partly reflected investment in the pipeline, including the
development of Enhertu and
the ending in 2019 of the release of the upfront funding of
Lynparza development as
part of the aforementioned collaboration
with MSD; Core R&D Expense increased by 8% in the half (9% at
CER) to $2,712m. The increase in Core Total Operating Expense was
also driven by additional SG&A investment in Oncology-medicine
launches and AstraZeneca’s further expansion in China; Core
SG&A Expense increased in the half by 2% (5% at CER) to
$4,353m
-
The Reported
Operating Profit Margin increased in the half by six percentage
points to 20%; the Core Operating Profit Margin increased by two
percentage points to 29%
-
Reported EPS of
$1.17 in the half, representing an increase of 108% (106% at CER).
Core EPS increased by 24% (26% at CER) to $2.01. This was despite
an increase in the weighted-average number of shares to 1,312m (H1
2019: 1,289m)
-
Net Cash Inflow
from Operating Activities of $1,179m in the half represented a
year-on-year increase of $688m, reflecting a $914m improvement in
Reported Operating Profit to $2,504m
-
An unchanged first
interim dividend of $0.90 per share
Commercial summary
Oncology
Total
Revenue increased by 28% in the half (31% at CER) to
$5,324m.
Table 2: Select Oncology medicine performances
|
|
H1 2020
|
Q2 2020
|
||||
|
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
|||
|
Tagrisso: Product
Sales
|
2,016
|
43
|
45
|
1,034
|
32
|
35
|
|
Imfinzi: Product
Sales
|
954
|
51
|
52
|
492
|
46
|
48
|
|
Lynparza: Product
Sales
|
816
|
57
|
60
|
419
|
48
|
52
|
|
Calquence: Product Sales
|
195
|
n/m
|
n/m
|
107
|
n/m
|
n/m
|
|
Enhertu: Collaboration
Revenue
|
36
|
n/m
|
n/m
|
22
|
n/m
|
n/m
|
New CVRM
Total
Revenue increased by 8% in the half (11% at CER) to
$2,265m.
Table 3: Select New CVRM medicine performances
|
|
H1 2020
|
Q2 2020
|
||||
|
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
|||
|
Farxiga: Product
Sales
|
848
|
17
|
21
|
443
|
17
|
23
|
|
Brilinta: Product
Sales
|
845
|
15
|
17
|
437
|
12
|
16
|
|
Bydureon: Product
Sales
|
216
|
(24)
|
(23)
|
116
|
(18)
|
(17)
|
|
Lokelma: Product
Sales
|
28
|
n/m
|
n/m
|
17
|
n/m
|
n/m
|
|
Roxadustat: Collaboration Revenue
|
11
|
n/m
|
n/m
|
9
|
n/m
|
n/m
|
Respiratory & Immunology
Total
Revenue increased by 5% in the half (7% at CER) to
$2,676m.
Table 4: Select Respiratory & Immunology medicine
performances
|
|
H1 2020
|
Q2 2020
|
||||
|
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
|||
|
Symbicort: Product
Sales
|
1,442
|
23
|
26
|
653
|
12
|
15
|
|
Pulmicort: Product
Sales
|
477
|
(33)
|
(32)
|
97
|
(71)
|
(69)
|
|
Fasenra: Product
Sales
|
426
|
44
|
45
|
227
|
36
|
37
|
Sales
of Pulmicort, of which the
majority were in China, were adversely impacted in the half by the
effects of COVID-19. Pulmicort sales in Emerging Markets
declined by 36% (34% at CER) to $371m in the first half and by 78%
(76% at CER) to $58m in the second quarter.
Emerging Markets
As the
Company’s largest region, at 34% of Total Revenue, Emerging
Markets increased by 9% in the half (15% at CER) to $4,329m,
including:
-
A China increase of
10% in the half (14% at CER) to $2,659m; the performance was
adversely impacted by the aforementioned effects of COVID-19 on
sales of Pulmicort. Q2 2020
Total Revenue increased by 7% (12% at CER) to $1,243m
-
An ex-China
increase of 8% in the half (15% at CER) to $1,671m. Q2 2020 Total
Revenue increased by 4% (15% at CER) to $813m
Sustainability summary
Recent
developments and progress against the Company’s
sustainability priorities are reported below:
a)
Access to healthcare
During
the period, AstraZeneca advanced its commitment to broad and
equitable global access to the University of Oxford’s
COVID-19 vaccine, AZD1222, following landmark agreements with the
US Biomedical Advanced Research and Development Authority (BARDA)
for the development, production and delivery of the vaccine and
parallel agreements with the UK Government,
Europe’s
Inclusive Vaccine Alliance (IVA), the Coalition for Epidemic
Preparedness Innovations (CEPI) and Gavi, The Vaccine Alliance
(GAVI). In addition, the Company reached a licensing
agreement with Serum Institute of India (SII) to supply
low-and-middle-income countries and agreements with R-Pharm in
Russia and SK Biopharmaceuticals Co., Ltd in the Republic of Korea
to manufacture and export for other global markets. Across the
world, these parallel agreements helped to provide total
manufacturing capacity of over two billion doses of the vaccine to
support broad and equitable access, at no profit to AstraZeneca
during the pandemic.
b)
Environmental protection
Pascal
Soriot was one of 17613 business leaders
from member companies of the Science-Based
Targets initiative that signed a recent statement
urging governments around the world to align their COVID-19
economic aid and recovery efforts with the latest climate science,
which was announced by
the UN Global Compact (UNGC) in May 2020.
c)
Ethics and transparency
Highlighting
the Company’s continued commitment to inclusion and
diversity, AstraZeneca was recognised by DiversityInc as
one of the 2020 Top 50 Companies
for Diversity; the Company was also named by DiversityInc as
a Top Company for lesbian, gay, bisexual, and transgender (LGBT)
employees.
A more
extensive sustainability update is provided later in this
announcement.
Notes
The
following notes refer to pages one to five.
1.
Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Koselugo, Farxiga, Brilinta, Lokelma, roxadustat, Fasenra, Bevespi and Breztri. The new medicines are pillars
in the three therapy areas of Oncology, Cardiovascular (CV), Renal
& Metabolism (CVRM), and Respiratory & Immunology and are
important platforms for future growth. The Total Revenue of
Enhertu and roxadustat in
the half entirely reflected Ongoing Collaboration
Revenue.
2.
Constant exchange
rates. These are financial measures that are not accounted for
according to generally accepted accounting principles (GAAP)
because they remove the effects of currency movements from Reported
results.
3.
Not
meaningful.
4.
Reported financial
measures are the financial results presented in accordance with
International Financial Reporting Standards (IFRS), as issued by
the International Accounting Standards Board and adopted by the EU.
The UK is in the process of establishing its post-Brexit
IFRS-adoption authority, which is expected to be operational later
in 2020, but for the current time, will follow the EU approval
process.
5.
Earnings per
share.
6.
Core financial
measures. These are non-GAAP financial measures because, unlike
Reported performance, they cannot be derived directly from the
information in the Group’s Interim Financial Statements. See
the operating and financial review for a definition of Core
financial measures and a reconciliation of Core to Reported
financial measures.
7.
Defined here as
Oncology, New CVRM and Respiratory & Immunology.
8.
New CVRM comprises
Brilinta, Renal and
Diabetes medicines.
9.
A severe immune
reaction in which the body releases too many cytokines into the
blood too quickly. Cytokines are cell signalling proteins that aid
communication in innate and adaptive immune responses, stimulating
cell movement towards sites of inflammation and
infection.
10.
FibroGen and
AstraZeneca are collaborating on the development and
commercialisation of roxadustat in the US, China, and other global
markets. FibroGen and Astellas Pharma Inc. (Astellas) are
collaborating on the development and commercialisation of
roxadustat in territories including Japan, Europe, the Commonwealth
of Independent States, the Middle East and South
Africa.
11.
Merck & Co.,
Inc., Kenilworth, NJ, US, known as MSD outside the US and
Canada.
12.
Gross Profit is
defined as Total Revenue minus Cost of Sales. The calculation of
Reported and Core Gross Profit Margin excludes the impact of
Collaboration Revenue and any associated costs, thereby reflecting
the underlying performance of Product Sales.
13.
As of 1 July
2020.
Table 5: Pipeline highlights
The
following table highlights significant developments in the
late-stage pipeline since the prior results
announcement:
|
Regulatory
approvals
|
- Lynparza - ovarian cancer (1st line,
HRD+1) (PAOLA-1) (US)
- Lynparza - pancreatic cancer (1st line,
BRCAm2) (EU)
- Lynparza - prostate cancer (2nd line,
HRRm3) (US)
- Bevespi - COPD8 (CN)
- Breztri - COPD (US)
|
|
Regulatory
submission acceptances and/or submissions
|
- Enhertu - breast cancer (3rd line,
HER2+9) (EU)
- Enhertu - gastric cancer (3rd line,
HER2+) (JP)
- Brilinta/Brilique - stroke (THALES) (US,
EU)
|
|
Major
Phase III data readouts or other significant
developments
|
- Enhertu - breast cancer (3rd line,
HER2+): accelerated assessment (EU)
- Enhertu - gastric cancer (HER2+):
Orphan Drug Designation, Breakthrough Therapy Designation
(US)
- Calquence - CLL14: positive opinion (EU)
- selumetinib -
NF115: orphan drug designation
(JP)
- Farxiga - CKD16: primary, all secondary endpoints
met
- Brilinta - stroke (THALES): Priority
Review (US)
|
Table 6: Pipeline - anticipated major news flow
Innovation
is critical to addressing unmet patient needs and is at the heart
of the Company’s growth strategy. The focus on research and
development is designed to yield strong and sustainable results
from the pipeline.
|
Timing
|
News
flow
|
|
H2 2020
|
- Tagrisso - adjuvant NSCLC
(EGFRm17): regulatory submission
- Imfinzi - unresectable18, Stage III NSCLC (PACIFIC-2): data
readout
- Imfinzi - ES-SCLC: regulatory decision
(EU, JP)
- Imfinzi +/- treme19 - liver cancer (1st line): data
readout, regulatory submission
- Lynparza - ovarian cancer (1st line)
(PAOLA-1): regulatory decision (EU, JP)
- Lynparza - ovarian cancer (3rd line,
BRCAm): regulatory submission
- Lynparza - breast cancer (BRCAm):
regulatory decision (CN)
- Lynparza - prostate cancer (2nd line):
regulatory decision (EU)
- Enhertu - breast cancer (3rd line,
HER2+): regulatory decision (EU)
- Enhertu - gastric cancer (3rd line,
HER2+): regulatory decision (JP)
- Calquence - CLL: regulatory decision
(EU)
- Forxiga - T2D CVOT: regulatory decision
(CN)
- Forxiga - HF CVOT: regulatory decision
(EU, JP)
- Farxiga - CKD: regulatory
submission
- Brilinta - stroke (THALES): regulatory
decision (US)
- Brilinta - stroke (THALES): regulatory
submission (CN)
- roxadustat -
anaemia in CKD: regulatory decision (US)
- Symbicort - mild asthma: regulatory
decision (CN)
- Symbicort - mild asthma: regulatory
submission (EU)
- Fasenra - nasal polyposis20: data readout
- PT010 - COPD:
regulatory decision (EU)
- tezepelumab -
severe asthma: data readout
- anifrolumab - lupus
(SLE21): regulatory submission
- AZD1222 -
SARS-CoV-2: data readout, regulatory submission
|
|
H1 2021
|
- Imfinzi - unresectable, Stage III NSCLC
(PACIFIC-2): regulatory submission
- Imfinzi - NSCLC (1st line) (PEARL):
data readout
- Imfinzi +/- treme - head & neck
cancer (1st line): data readout, regulatory submission
- Lynparza - pancreatic cancer (1st line,
BRCAm): regulatory decision (JP)
- Lynparza - prostate cancer (2nd line):
regulatory decision (JP)
- Lynparza - adjuvant breast cancer: data
readout
- Calquence - CLL: regulatory decision
(JP)
- Koselugo - NF1 regulatory decision
(EU)
- Forxiga - HF CVOT: regulatory decision
(CN)
- Brilique/Brilinta - CAD/T2D CVOT: regulatory
decision (EU, JP, CN)
- Brilique - stroke (THALES): regulatory
decision (EU)
- Fasenra - nasal polyposis: regulatory
submission
- tezepelumab -
severe asthma: regulatory submission
|
|
H2 2021
|
- Imfinzi - NSCLC (1st line) (PEARL):
regulatory submission
- Imfinzi - adjuvant bladder cancer: data
readout
- Imfinzi - liver cancer (locoregional):
data readout, regulatory submission
- Imfinzi - biliary tract cancer: data
readout
- Imfinzi +/- treme - NSCLC (1st line)
(POSEIDON): data readout (OS), regulatory submission
- Lynparza - adjuvant breast cancer:
regulatory submission
- Lynparza - prostate cancer (1st line,
castration-resistant): data readout, regulatory
submission
- Enhertu - breast cancer (3rd line,
HER2+) (Phase III): data readout
- Enhertu - breast cancer (2nd line,
HER2+): data readout, regulatory submission
- Enhertu - breast cancer (HER2
low22): data readout
- Calquence - CLL (2nd line) (ELEVATE
R/R): data readout, regulatory submission
- Farxiga - HF (HFpEF23): data readout, regulatory
submission
- PT027 - asthma:
data readout, regulatory submission
|
Conference call
A
conference call and webcast for investors and analysts will begin
at 11:45am UK time today. Details can be accessed via astrazeneca.com.
Report calendar
The
Company intends to publish its year-to-date and third-quarter
results on Thursday, 5 November 2020.
AstraZeneca
AstraZeneca
(LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development and
commercialisation of prescription medicines, primarily for the
treatment of diseases in three therapy areas - Oncology, CVRM, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit astrazeneca.com
and follow the Company on Twitter @AstraZeneca.
Contacts
For
details on how to contact the Investor Relations Team, please
click
here. For Media contacts, click
here.
Operating and financial review
All
narrative on growth and results in this section is based on actual
exchange rates, and financial figures are in US$ millions ($m),
unless stated otherwise. The performance shown in this announcement
covers the six-month period to 30 June 2020 (the half or H1 2020)
and the three-month period to 30 June 2020 (the second quarter or
Q2 2020) compared to the six-month period to 30 June 2019 (H1 2019)
and three-month period to 30 June 2019 (Q2 2019) respectively,
unless stated otherwise.
Core
financial measures, EBITDA, Net Debt, Initial Collaboration Revenue
and Ongoing Collaboration Revenue are non-GAAP financial measures
because they cannot be derived directly from the Group’s
Interim Financial Statements. Management believes that these
non-GAAP financial measures, when provided in combination with
Reported results, will provide investors and analysts with helpful
supplementary information to understand better the financial
performance and position of the Group on a comparable basis from
period to period. These non-GAAP financial measures are not a
substitute for, or superior to, financial measures prepared in
accordance with GAAP. Core financial measures are adjusted to
exclude certain significant items, such as:
-
Amortisation and
impairment of intangible assets, including impairment reversals but
excluding any charges relating to IT assets
-
Charges and
provisions related to restructuring programmes, which includes
charges that relate to the impact of restructuring programmes on
capitalised IT assets
-
Other specified
items, principally comprising acquisition-related costs, which
include fair-value adjustments and the imputed finance charge
relating to contingent consideration on business combinations and
legal settlements
Details
on the nature of Core financial measures are provided on page 80 of
the Annual
Report and Form 20-F Information 2019. Reference should be
made to the Reconciliation of Reported to Core financial measures
table included in the financial performance section of this
announcement.
EBITDA
is defined as Reported Profit Before Tax after adding back Net
Finance Expense, results from Joint Ventures and Associates and
charges for Depreciation, Amortisation and Impairment. Reference
should be made to the Reconciliation of Reported Profit Before Tax
to EBITDA included in the financial performance section of this
announcement.
Net
Debt is defined as Interest-bearing loans and borrowings and Lease
liabilities, net of Cash and cash equivalents, Other investments,
and net Derivative financial instruments. Reference should be made
to Note 3 ‘Net Debt’ included in the Notes to the
Interim Financial Statements in this announcement.
Ongoing
Collaboration Revenue is defined as Collaboration Revenue excluding
Initial Collaboration Revenue (which is defined as Collaboration
Revenue that is recognised at the date of completion of an
agreement or transaction, in respect of upfront consideration).
Ongoing Collaboration Revenue comprises, among other items,
royalties, milestone revenue and profit-sharing income. Reference
should be made to the Collaboration Revenue table in this operating
and financial review.
The
Company strongly encourages investors and analysts not to rely on
any single financial measure, but to review AstraZeneca’s
financial statements, including the Notes thereto and other
available Company reports, carefully and in their
entirety.
Due to
rounding, the sum of a number of dollar values and percentages may
not agree to totals.
Table 7: Total Revenue by therapy area
Specialty-care
medicines comprise all Oncology medicines, Brilinta, Lokelma, roxadustat and Fasenra. At 53% of Total Revenue (H1
2019: 46%), specialty-care medicines increased by 28% in the half
(30% at CER) to $6,634m.
|
|
H1 2020
|
Q2 2020
|
||||||
|
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
|||||
|
Oncology
|
5,324
|
42
|
28
|
31
|
2,806
|
45
|
25
|
28
|
|
BioPharmaceuticals
|
4,941
|
39
|
7
|
9
|
2,285
|
36
|
(1)
|
2
|
|
New CVRM
|
2,265
|
18
|
8
|
11
|
1,163
|
19
|
10
|
13
|
|
Respiratory & Immunology
|
2,676
|
21
|
5
|
7
|
1,122
|
18
|
(11)
|
(8)
|
|
Other
medicines
|
2,364
|
19
|
(7)
|
(4)
|
1,184
|
19
|
(6)
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
12,629
|
100
|
12
|
14
|
6,275
|
100
|
8
|
11
|
Table 8: Top-ten medicines by Total Revenue
|
Medicine
|
Therapy Area
|
H1 2020
|
Q2 2020
|
|||||
|
$m
|
% of total
|
% change
|
$m
|
% change
|
||||
|
Actual
|
CER
|
Actual
|
CER
|
|||||
|
Tagrisso
|
Oncology
|
2,016
|
16
|
43
|
45
|
1,034
|
32
|
35
|
|
Symbicort
|
Respiratory & Immunology
|
1,442
|
11
|
23
|
26
|
653
|
12
|
15
|
|
Imfinzi
|
Oncology
|
954
|
8
|
51
|
52
|
492
|
46
|
48
|
|
Lynparza
|
Oncology
|
951
|
8
|
64
|
66
|
554
|
62
|
65
|
|
Farxiga
|
CVRM
|
850
|
7
|
17
|
21
|
444
|
17
|
23
|
|
Brilinta
|
CVRM
|
845
|
7
|
15
|
17
|
437
|
12
|
16
|
|
Nexium
|
Other medicines
|
731
|
6
|
(5)
|
(3)
|
384
|
(4)
|
(1)
|
|
Crestor
|
CVRM
|
583
|
5
|
(10)
|
(7)
|
282
|
(9)
|
(6)
|
|
Zoladex
|
Oncology
|
484
|
4
|
22
|
27
|
257
|
28
|
34
|
|
Pulmicort
|
Respiratory & Immunology
|
477
|
4
|
(33)
|
(32)
|
97
|
(71)
|
(69)
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
9,333
|
74
|
20
|
22
|
4,634
|
14
|
17
|
Table 9: Collaboration Revenue
Other Ongoing Collaboration Revenue included Zoladex, Farxiga, Eklira, Nexium OTC24 and other royalties. No Initial
Collaboration Revenue was recorded in the half.
|
|
H1 2020
|
Q2 2020
|
|||||
|
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
||||
|
Lynparza: regulatory milestone
revenue
|
135
|
50
|
n/m
|
n/m
|
135
|
n/m
|
n/m
|
|
Enhertu: profit
share
|
36
|
13
|
n/m
|
n/m
|
22
|
n/m
|
n/m
|
|
Roxadustat: profit share
|
11
|
4
|
n/m
|
n/m
|
9
|
n/m
|
n/m
|
|
Other Collaboration Revenue
|
88
|
33
|
24
|
25
|
61
|
36
|
36
|
|
|
|
|
|
|
|
|
|
|
Total
|
270
|
100
|
n/m
|
n/m
|
227
|
n/m
|
n/m
|
Total Revenue
The
performance of the Company’s medicines is shown below, with a
geographical split of Product Sales shown in Note 7.
Table 10: Therapy area and medicine performance - H1
2020
|
Product Sales: therapy area
|
Medicine
|
H1 2020
|
|||
|
$m
|
% of total Product Sales
|
% change
|
|||
|
Actual
|
CER
|
||||
|
Oncology
|
Tagrisso
|
2,016
|
16
|
43
|
45
|
|
Imfinzi
|
954
|
8
|
51
|
52
|
|
|
Lynparza
|
816
|
7
|
57
|
60
|
|
|
Calquence
|
195
|
2
|
n/m
|
n/m
|
|
|
Koselugo
|
7
|
-
|
n/m
|
n/m
|
|
|
Zoladex
|
442
|
4
|
13
|
18
|
|
|
Faslodex
|
312
|
3
|
(40)
|
(38)
|
|
|
Iressa
|
147
|
1
|
(42)
|
(40)
|
|
|
Arimidex
|
107
|
1
|
(3)
|
-
|
|
|
Casodex
|
89
|
1
|
(15)
|
(13)
|
|
|
Others
|
26
|
-
|
(50)
|
(47)
|
|
|
Total Oncology
|
5,111
|
41
|
26
|
28
|
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
848
|
7
|
17
|
21
|
|
Brilinta
|
845
|
7
|
15
|
17
|
|
|
Onglyza
|
256
|
2
|
(5)
|
(3)
|
|
|
Bydureon
|
216
|
2
|
(24)
|
(23)
|
|
|
Byetta
|
35
|
-
|
(36)
|
(35)
|
|
|
Other diabetes
|
23
|
-
|
3
|
6
|
|
|
Lokelma
|
28
|
-
|
n/m
|
n/m
|
|
|
Crestor
|
582
|
5
|
(10)
|
(8)
|
|
|
Seloken/Toprol-XL
|
395
|
3
|
-
|
6
|
|
|
Atacand
|
126
|
1
|
19
|
25
|
|
|
Others
|
106
|
1
|
(20)
|
(18)
|
|
|
BioPharmaceuticals:
total CVRM
|
3,460
|
28
|
3
|
6
|
|
|
BioPharmaceuticals: Respiratory & Immunology
|
Symbicort
|
1,442
|
12
|
23
|
26
|
|
Pulmicort
|
477
|
4
|
(33)
|
(32)
|
|
|
Fasenra
|
426
|
3
|
44
|
45
|
|
|
Daliresp/Daxas
|
106
|
1
|
1
|
2
|
|
|
Bevespi
|
22
|
-
|
10
|
10
|
|
|
Breztri
|
11
|
-
|
n/m
|
n/m
|
|
|
Others
|
184
|
1
|
(20)
|
(18)
|
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
2,668
|
22
|
5
|
7
|
|
|
Other medicines
|
Nexium
|
714
|
6
|
(5)
|
(3)
|
|
Synagis
|
176
|
1
|
18
|
18
|
|
|
Losec/Prilosec
|
99
|
1
|
(32)
|
(30)
|
|
|
Seroquel XR/IR
|
63
|
1
|
(9)
|
(8)
|
|
|
Others
|
68
|
1
|
(32)
|
(31)
|
|
|
Total other medicines
|
1,120
|
9
|
(8)
|
(6)
|
|
|
|
Total Product Sales
|
12,359
|
100
|
11
|
13
|
|
|
|||||
|
Total Collaboration Revenue
|
270
|
|
n/m
|
n/m
|
|
|
|
|||||
|
Total Revenue
|
12,629
|
|
12
|
14
|
|
Table 11: Therapy area and medicine performance - Q2
2020
|
Product Sales: therapy area
|
Medicine
|
Q2 2020
|
|||
|
$m
|
% of total Product Sales
|
% change
|
|||
|
Actual
|
CER
|
||||
|
Oncology
|
Tagrisso
|
1,034
|
17
|
32
|
35
|
|
Imfinzi
|
492
|
8
|
46
|
48
|
|
|
Lynparza
|
419
|
7
|
48
|
52
|
|
|
Calquence
|
107
|
2
|
n/m
|
n/m
|
|
|
Koselugo
|
7
|
-
|
n/m
|
n/m
|
|
|
Zoladex
|
217
|
4
|
10
|
17
|
|
|
Faslodex
|
146
|
2
|
(45)
|
(43)
|
|
|
Iressa
|
70
|
1
|
(41)
|
(38)
|
|
|
Arimidex
|
58
|
1
|
(4)
|
-
|
|
|
Casodex
|
47
|
1
|
(17)
|
(15)
|
|
|
Others
|
12
|
-
|
(59)
|
(55)
|
|
|
Total Oncology
|
2,609
|
43
|
20
|
24
|
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
443
|
7
|
17
|
23
|
|
Brilinta
|
437
|
7
|
12
|
16
|
|
|
Onglyza
|
115
|
2
|
(1)
|
3
|
|
|
Bydureon
|
116
|
2
|
(18)
|
(17)
|
|
|
Byetta
|
15
|
-
|
(42)
|
(41)
|
|
|
Other diabetes
|
10
|
-
|
(9)
|
(5)
|
|
|
Lokelma
|
17
|
-
|
n/m
|
n/m
|
|
|
Crestor
|
281
|
5
|
(10)
|
(6)
|
|
|
Seloken/Toprol-XL
|
218
|
4
|
29
|
38
|
|
|
Atacand
|
59
|
1
|
6
|
14
|
|
|
Others
|
48
|
1
|
(23)
|
(20)
|
|
|
BioPharmaceuticals:
total CVRM
|
1,759
|
29
|
6
|
10
|
|
|
BioPharmaceuticals: Respiratory & Immunology
|
Symbicort
|
653
|
11
|
12
|
15
|
|
Pulmicort
|
97
|
2
|
(71)
|
(69)
|
|
|
Fasenra
|
227
|
4
|
36
|
37
|
|
|
Daliresp/Daxas
|
53
|
1
|
(7)
|
(7)
|
|
|
Bevespi
|
10
|
-
|
(1)
|
(3)
|
|
|
Breztri
|
7
|
-
|
n/m
|
n/m
|
|
|
Others
|
70
|
1
|
(30)
|
(28)
|
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,117
|
18
|
(11)
|
(8)
|
|
|
Other medicines
|
Nexium
|
377
|
6
|
(4)
|
(1)
|
|
Synagis
|
90
|
1
|
(5)
|
(5)
|
|
|
Losec/Prilosec
|
45
|
1
|
(34)
|
(31)
|
|
|
Seroquel XR/IR
|
27
|
-
|
(16)
|
(14)
|
|
|
Others
|
24
|
-
|
(53)
|
(52)
|
|
|
Total other medicines
|
563
|
9
|
(12)
|
(10)
|
|
|
|
Total Product Sales
|
6,048
|
100
|
6
|
9
|
|
|
|||||
|
Total Collaboration Revenue
|
227
|
|
n/m
|
n/m
|
|
|
|
|||||
|
Total Revenue
|
6,275
|
|
8
|
11
|
|
Total Revenue summary
Oncology
Total
Revenue of $5,324m in the half; an increase of 28% (31% at CER).
This included Lynparza
Collaboration Revenue of $135m. The performance of Enhertu was reflected entirely in
Collaboration Revenue.
Oncology
represented 42% of overall Total Revenue (H1 2019:
37%).
Tagrisso
Tagrisso has received regulatory approval in 86 countries,
including the US, China, in the EU and Japan for the 1st-line
treatment of patients with EGFRm NSCLC. To date, reimbursement has
been granted in 28 countries in this setting, with further
reimbursement decisions anticipated in the second half of the year.
This followed Tagrisso’s initial approval in 89
countries, including the US, China, in the EU and Japan for the
treatment of patients with EGFR T790M25-mutated NSCLC.
Total
Revenue, entirely comprising Product Sales, amounted to $2,016m in
the half and represented growth of 43% (45% at CER). This was
partly driven by the aforementioned regulatory approvals and
reimbursements in the 1st-line setting. Continued growth was also
delivered in the 2nd-line setting, for example, within Europe and
Emerging Markets. Sales in the US increased by 30% to $725m, despite adverse inventory movements
in the second quarter. Demand growth continued as Tagrisso retained its position as the
standard of care (SoC) in the 1st-line setting.
In
Emerging Markets, Tagrisso
sales increased by 81% in the half (89% at CER) to $595m, with
notable growth in China, following the admission in 2019 to the
China National Drug Reimbursement List (NRDL) in the 2nd-line
setting. Tagrisso Total
Revenue in Japan increased by 17% (16% at CER) to $340m. In Europe,
sales of $325m in the half represented an increase of 53% (58% at
CER), driven by its use in the 1st-line setting, as more
reimbursements were granted.
Imfinzi
Imfinzi has received regulatory approval in 62 countries,
including the US, China, in the EU and Japan for the treatment of
patients with unresectable, Stage III NSCLC whose disease has not
progressed following platinum-based chemoradiation therapy (CRT).
The number of reimbursements increased to 27 in the
half. During the period,
Imfinzi
was also approved for the treatment of
ES-SCLC patients in eight countries, including the US. It is
already approved for the 2nd-line treatment of patients with
locally advanced or metastatic urothelial carcinoma (bladder
cancer) in 17 countries, including the US.
Total
Revenue, entirely comprising Product Sales, amounted to $954m in
the half and represented growth of 51% (52% at CER), predominantly
for the treatment of unresectable, Stage III NSCLC. Total Revenue
in the US increased by 21% to $574m; in Japan, growth of 44% (43%
at CER) represented sales of $124m. Sales in Europe increased by
179% (188% at CER) to $167m, reflecting a growing number of
reimbursements, while sales in Emerging Markets increased by 428%
(459% at CER) to $63m, following recent regulatory approvals and
launches.
Lynparza
Lynparza has received regulatory approval in 75 countries
for the treatment of ovarian cancer; it has also been approved in
67 countries for the treatment of metastatic breast cancer, and in
38 countries, including the US, for
the treatment of pancreatic cancer. Finally, it has also received
regulatory approval in the US for the 2nd-line treatment of HRRm
prostate cancer.
Total
Revenue amounted to $951m in the half and represented growth of 64%
(66% at CER); $135m of Lynparza Collaboration Revenue,
reflecting regulatory-milestone receipts, was recorded in the half.
The strong performance was geographically spread, with launches
continuing in Emerging Markets and the Established Rest of World
region (RoW).
US
sales increased by 55%, driven by the launch in the 1st-line BRCAm
ovarian cancer setting at the end of 2018. Lynparza continued to be the leading
medicine in the poly ADP ribose polymerase (PARP)-inhibitor class,
as measured by total prescription volumes in both ovarian and
breast cancer. Sales in Europe increased by 51% (56% at CER) to
$198m, reflecting increasing levels of reimbursement and
BRCAm-testing rates, as well as successful recent 1st-line ovarian
cancer launches, including in the UK and Germany.
Japan
sales of Lynparza amounted
to $77m, representing growth of 32% (31% at CER). Emerging Markets
sales of $120m, up by 104% (117% at CER), were a result of the
regulatory approval of Lynparza as a 2nd-line maintenance
treatment of patients with ovarian cancer by the China National
Medical Products Administration (NMPA) in 2019. Lynparza was admitted to the China NRDL
for the same indication, with effect from January
2020.
Enhertu
Global
sales, recorded by Daiichi Sankyo, amounted to $77m. This reflected
sales predominantly in the US, where Enhertu was launched at the start of
the year and where Daiichi Sankyo is the principal. Enhertu was approved by the US Food and Drug
Administration (FDA) for the treatment
of 3rd-line HER2+ breast cancer at the end of 2019. Total Revenue,
entirely comprising Collaboration Revenue recorded by AstraZeneca,
amounted to $36m in the half.
Calquence
Total
Revenue, entirely comprising Product Sales, amounted to $195m in
the half and represented growth of 204% (205% at CER), with the
overwhelming majority of sales in the US. Calquence was approved by the US FDA
for the treatment of CLL and small lymphocytic lymphoma in November
2019 and received regulatory approval in this indication in an
additional 12 countries. Calquence has also received 17 other
regulatory approvals for the treatment of patients with mantle cell
lymphoma.
Koselugo
Total
Revenue, entirely comprising Product Sales in the US, amounted to
$7m in the half, following its launch during the period.
Koselugo was approved by
the US FDA for the treatment of paediatric patients aged two years
and older with NF1 who have symptomatic, inoperable plexiform
neurofibromas.
Legacy: Zoladex
Total
Revenue, predominantly comprising Product Sales, amounted to $484m
in the half and represented growth of 22% (27% at
CER).
Emerging
Markets sales of Zoladex
increased by 22% (29% at CER) to $288m reflecting increased use and
access in prostate cancer. Sales in Europe increased by 5% (8% at
CER) to $68m. In the Established RoW region, sales declined by 7%
(6% at CER) to $81m, driven by the effects of increased
competition.
Legacy: Faslodex
Total
Revenue, entirely comprising Product Sales, amounted to $312m in
the half and represented a decline of 40% (38% at
CER).
Emerging
Markets sales of Faslodex
increased by 4% (10% at CER) to $100m. US sales, however, declined
by 87% to $34m, reflecting the launch in 2019 of multiple generic
Faslodex medicines. In
Europe, where generic competitor medicines are established, sales
increased by 6% (9% at CER) to $116m, while in Japan, sales
declined by 5% (7% at CER) to $58m, driven by a mandated price
reduction in the second quarter.
Legacy: Iressa
Total
Revenue, entirely comprising Product Sales, amounted to $147m in
the half and represented a decline of 42% (40% at CER). Sales in
Emerging Markets declined by 27% (24% at CER) to $120m, reflecting
the growing impact of Iressa’s inclusion on the China
volume-based procurement programme.
BioPharmaceuticals: CVRM
Total
Revenue increased by 3% in the first half (6% at CER) to $3,478m
and represented 28% of Total Revenue (H1 2019: 30%). This included
roxadustat Ongoing Collaboration Revenue of $11m, as well as sales
of Crestor and other legacy
medicines.
New
CVRM Total Revenue, which excludes sales of Crestor and other legacy medicines,
increased by 8% in the half (11% at CER) to $2,265m, reflecting the
performances of Farxiga and
Brilinta. New CVRM
represented 65% of overall CVRM Total Revenue in the half (H1 2019:
62%).
Farxiga
Total
Revenue, predominantly comprising Product Sales, amounted to $850m
in the half and represented growth of 17% (21% at
CER).
Emerging
Markets sales increased by 49% (59% at CER) to $306m. In China,
Farxiga was admitted to the
NRDL with effect from the start of 2020; as expected, this
adversely impacted pricing. This effect, however, was more than
offset by the volume benefit derived from the launch within the
NRDL listing. The performance also reflected continued growth in
the sodium-glucose layer transport protein 2 inhibitor class at the
expense of the dipeptidyl-peptidase 4 (DPP-4) inhibitor
class.
US
sales declined by 12% to $237m, reflecting the impact of
competitive activity on pricing and the mix of channel sales that
outweighed an encouraging level of volume growth. There were,
however, favourable movements in the share of new-to-brand
prescriptions, a result of a label update in Q3 2019 to reflect
results from the DECLARE CVOT and the more recent HF (with reduced
ejection fraction) label.
Sales
in Europe increased by 25% (29% at CER) to $223m, partly reflecting
growth in the class and an acceleration of new-to-brand
prescriptions, following a similar DECLARE-trial label update. In
Japan, sales to the collaborator, Ono Pharmaceutical Co., Ltd,
which records in-market sales, increased by 14% (12% at CER) to
$43m.
Brilinta
Total
Revenue, entirely comprising Product Sales, amounted to $845m in
the half and represented growth of 15% (17% at CER). Patient uptake
continued in the treatment of acute coronary syndrome and high-risk
post-myocardial infarction (MI).
Emerging
Markets sales increased by 34% (40% at CER) to $291m. US sales, at
$351m, represented an increase of 9%, driven primarily by
increasing levels of demand in both hospital and retail settings,
as well as a lengthening in the average-weighted duration of
treatment, reflecting the growing impact of 90-day prescriptions.
Sales of Brilique in Europe
increased by 2% in the half (5% at CER) to $173m, mainly reflecting
performances in Germany, France and Italy.
Onglyza
Total
Revenue, entirely comprising Product Sales, amounted to $256m in
the half and represented a decline of 5% (3% at CER).
Sales
in Emerging Markets increased by 15% (21% at CER) to $100m, driven
by the performance in China. US sales of Onglyza declined by 12% in the half to
$105m; Europe sales declined by 21% (18% at CER) to $29m. This
highlighted the broader trend of a shift away from the DPP-4
inhibitor class. Given the significant future potential of
Farxiga, the Company
continues to prioritise commercial support over Onglyza.
Bydureon
Total
Revenue, entirely comprising Product Sales, amounted to $216m in
the half and represented a decline of 24% (23% at
CER).
US
sales of $185m reflected a decline of 21% in the half, resulting
from competitive pressures and the impact of managed markets.
Patients continue to transition from the dual-chamber pen to the
BCise device. Bydureon sales in Europe fell by 29%
(26% at CER) to $24m. Reflecting the recent and potential
performance of Bydureon, a
$102m intangible-asset impairment charge was recorded in the
half.
Qternmet
During
the period, the Company decided not to progress with the planned
launch of Qternmet (a
fixed-dose combination of metformin, Farxiga and Onglyza), reflecting adverse changes in
the competitive landscape.
Lokelma
Total
Revenue, entirely comprising Product Sales, amounted to $28m in the
half. Q2 2020 sales of $17m reflected sequential growth of 56% (58%
at CER) over Q1 2020.
The US
represented the overwhelming majority of sales, following the
recent launch of the medicine; Lokelma led new-to-brand prescription
market share during the period. The medicine has received
regulatory approval in a number of markets including in the EU,
China and Japan and for the treatment of hyperkalaemia, with
further launches in several markets anticipated soon.
Roxadustat
Total
Revenue, entirely comprising Ongoing Collaboration Revenue,
amounted to $11m in the half. The period saw a continued focus on
achieving hospital listings across China, with more than 40,000
patients being treated for anaemia in CKD with the medicine. The
China NMPA approved roxadustat for the treatment of anaemia in CKD
in dialysis-dependent (DD) and non-dialysis dependent (NDD)
patients in December 2018 and August 2019, respectively. Roxadustat
was admitted to the China NRDL with effect from January
2020.
In
China, the Company currently records its share of roxadustat gross
profit as Collaboration Revenue. During the period, FibroGen and
AstraZeneca entered into an amendment,
effective 1 July 2020, to revise the existing licence, development
and commercialisation agreement that was originally entered into on
30 July 2013, relating to the development and commercialisation of
roxadustat in China. The amendment establishes a jointly owned
entity that, once fully operational in 2021, will mean that
FibroGen is expected to recognise revenue based on its sales to the
entity, whereas AstraZeneca will likely recognise the overwhelming
majority of its future revenue in China as Product
Sales.
Legacy: Crestor
Total
Revenue, predominantly comprising Product Sales, amounted to $583m
in the half and represented a decline of 10% (7% at
CER).
Sales
in Emerging Markets declined by 9% (6% at CER) to $369m. The
performance was adversely impacted by the effect of volume-based
procurement in China. US sales declined by 17% to $45m. In Europe,
sales declined by 13% (12% at CER) to $65m while in Japan, where
AstraZeneca collaborates with Shionogi Co., Ltd, sales declined by
5% (6% at CER) to $81m.
BioPharmaceuticals: Respiratory & Immunology
Total
Revenue increased by 5% in the half (7% at CER) to $2,676m and
represented 21% of Total Revenue (H1 2019: 22%). This included
Ongoing Collaboration Revenue of $8m from Duaklir, Eklira and Siliq.
Symbicort
Total
Revenue, entirely comprising Product Sales, amounted to $1,442m in
the half and represented growth of 23% (26% at CER).
US
sales grew by 46% to $558m in the half. An authorised-generic
version of Symbicort was
launched in the US by
the Company’s collaborator, Prasco, in January 2020.
Symbicort also continued
its global market-volume and value leadership within the inhaled
corticosteroid / long-acting beta agonist (LABA) class. Emerging
Markets sales increased by 10% in the half (16% at CER) to $290m,
reflecting particularly strong performances in China and the Middle
East & Africa.
In
Europe, sales increased by 1% in the half (4% at CER) to $356m. In
Japan, sales increased by 53% (51% at CER) to $102m, supported by
the continued effect of AstraZeneca regaining full rights,
following termination in 2019 of the Astellas co-promotion
agreement; the increase was despite the market entry of a generic
medicine.
Pulmicort
Total
Revenue, entirely comprising Product Sales, amounted to $477m in
the half and represented a decline of 33% (32% at
CER).
Emerging
Markets, where Pulmicort
sales declined by 36% in the half (34% at CER) at $371m,
represented 78% of global total. The performance in China continued
to be impacted by COVID-19, with a significant reduction in the
number of paediatric patients attending outpatient nebulisation
rooms and adult elective procedures, where Pulmicort can be used in operative care
when oral corticosteroids are unsuitable. This was particularly
evident in the second quarter, when Pulmicort sales in Emerging Markets
declined by 78% (76% at CER) to $58m. The declines were also a
reflection of a particularly benign influenza season in China,
resulting in a significantly reduced number of asthma
exacerbations.
Sales
in the US declined by 36% to $36m, while they fell in Europe by 8%
(4% at CER) to $40m.
Fasenra
Fasenra has received regulatory approval in 58 countries,
including in the US, the EU and Japan for the treatment of patients
with severe, uncontrolled eosinophilic asthma. With further
regulatory reviews ongoing, Fasenra has already achieved
reimbursement in 41 countries. Total Revenue, entirely comprising
Product Sales, amounted to $426m in the half and represented growth
of 44% (45% at CER).
Sales
in the US increased by 31% in the half to $272m, supported by an
increase in the self-administration use as a result of COVID-19
restrictions. For the aforementioned treatment of patients,
Fasenra ended the half as
the leading novel biologic medicine in the US, as measured by
new-to-brand prescriptions. In Europe, sales of $88m in the half
represented an increase of 96% (102% at CER), reflecting a number
of successful launches. Sales in Japan increased by 21% (20% at
CER) to $46m. In its approved indication and among new patients,
Fasenra obtained the
leading market share of all novel biologic medicines in the
‘top-five’ European countries and in Japan. In Emerging
Markets, sales amounted to $7m in the half (H1 2019:
$1m).
Daliresp/Daxas
Total
Revenue, entirely comprising Product Sales, amounted to $106m in
the half and represented an increase of 1% (2% at
CER).
US
sales, representing 85% of the global total, increased by 1% to
$90m, driven by higher demand.
Bevespi
Total
Revenue, entirely comprising Product Sales, amounted to $22m in the
half and represented an increase of 10%.
Bevespi has been launched in the US, in a number of European
countries and in Japan. The global LABA / long acting muscarinic
antagonist class continued to grow more slowly than
expected.
Breztri
Total
Revenue, entirely comprising Product Sales, amounted to $11m in the
half (H1 2019: $nil).
Following
successful launches in Japan and China for the treatment of COPD,
Breztri was recently
approved in the US.
Other medicines (outside the three main therapy areas)
Total
Revenue, primarily comprising Product Sales, amounted to $1,151m in
the half, representing a decline of 8% (6% at CER). The performance
partly reflected the divestment of
global rights to Movantik, excluding Europe, Canada and
Israel, to RedHill Biopharma in April 2020. Other Total Revenue represented
9% of overall Total Revenue (H1 2019: 11%).
Nexium
Total
Revenue, predominantly comprising Product Sales, amounted to $731m
in the half; a decline of 5% (3% at CER). Emerging Markets sales of
Nexium were stable
(increasing by 4% at CER) at $370m. In Europe, sales increased by
20% (25% at CER) to $38m, while sales in the US declined by 30% to
$89m and in Japan, where AstraZeneca collaborates with Daiichi
Sankyo, they fell by 5% to $204m.
Losec/Prilosec
Total
Revenue, entirely comprising Product Sales, amounted to $99m in the
half, a decline of 32% (30% at CER). Sales in Emerging Markets
declined by 15% (12% at CER) to $81m. Sales in Europe fell by 68%
to $10m, while in Japan, they declined by 45% (46% at CER) to
$5m.
Synagis
The
commercial rights to the sale and distribution of Synagis outside the US, held by AbbVie,
Inc (AbbVie) since 1997, will revert to AstraZeneca upon the expiry
of the current agreement on 30 June 2021. In general, the Company
will solely distribute and promote the medicine outside the US from
1 July 2021. The agreement with Swedish Orphan Biovitrum AB (publ),
for the rights to Synagis
in the US, was unaffected by this decision.
Regional Total Revenue
Table 12: Regional Total Revenue
|
|
H1 2020
|
Q2 2020
|
|||||
|
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
||||
|
Emerging Markets
|
4,329
|
34
|
9
|
15
|
2,056
|
6
|
13
|
|
China
|
2,659
|
21
|
10
|
14
|
1,243
|
7
|
12
|
|
Ex-China
|
1,671
|
13
|
8
|
15
|
813
|
4
|
15
|
|
|
|
|
|
|
|
|
|
|
US
|
4,177
|
33
|
13
|
13
|
2,085
|
10
|
10
|
|
|
|
|
|
|
|
|
|
|
Europe
|
2,447
|
19
|
17
|
20
|
1,244
|
12
|
15
|
|
|
|
|
|
|
|
|
|
|
Established RoW
|
1,676
|
13
|
7
|
7
|
890
|
2
|
3
|
|
Japan
|
1,232
|
10
|
3
|
2
|
679
|
(2)
|
(3)
|
|
Canada
|
298
|
2
|
33
|
35
|
143
|
28
|
35
|
|
Other Established
RoW
|
145
|
1
|
2
|
10
|
68
|
6
|
17
|
|
|
|
|
|
|
|
|
|
|
Total
|
12,629
|
100
|
12
|
14
|
6,275
|
8
|
11
|
Table 13: Emerging Markets therapy-area performance - Total
Revenue
|
|
H1 2020
|
Q2 2020
|
|||||
|
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
||||
|
Oncology
|
1,461
|
34
|
39
|
46
|
750
|
34
|
43
|
|
BioPharmaceuticals
|
1,480
|
34
|
-
|
5
|
608
|
(15)
|
(9)
|
|
New CVRM
|
719
|
17
|
38
|
46
|
387
|
37
|
48
|
|
Respiratory &
Immunology
|
761
|
18
|
(20)
|
(17)
|
221
|
(49)
|
(45)
|
|
Other medicines
|
1,389
|
32
|
(3)
|
2
|
697
|
4
|
11
|
|
|
|
|
|
|
|
|
|
|
Total
|
4,329
|
100
|
9
|
15
|
2,056
|
6
|
13
|
Table 14: Notable new-medicine performances in Emerging Markets -
Total Revenue
|
|
H1 2020
|
Q2 2020
|
|||||
|
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
||||
|
Tagrisso
|
595
|
14
|
81
|
89
|
315
|
65
|
74
|
|
Forxiga
|
306
|
7
|
49
|
59
|
165
|
49
|
62
|
|
Brilinta
|
291
|
7
|
34
|
40
|
156
|
30
|
39
|
|
Lynparza26
|
120
|
3
|
n/m
|
n/m
|
64
|
95
|
n/m
|
The new
medicines represented 32% of Emerging Markets Total Revenue (H1
2019: 20%). Total Revenue from specialty-care medicines increased
by 40% (47% at CER) to $1,771m and comprised 41% of Emerging
Markets sales in the half (H1 2019: 32%).
China
Total Revenue, which included $11m of roxadustat Ongoing
Collaboration Revenue, comprised 61% of Emerging Markets Total
Revenue in the half and increased by 10% (14% at CER) to $2,659m.
New-medicine Total Revenue in China, primarily driven by
Tagrisso and Lynparza in Oncology and Brilinta and Forxiga in New CVRM, delivered
particularly encouraging growth and represented 31% of China Total
Revenue (H1 2019: 17%). This performance was supplemented by strong
sales of Zoladex,
Seloken and Symbicort, despite the disappointing
performance from Pulmicort.
Ex-China
Emerging Markets, comprising entirely of Product Sales, increased
by 8% in the half (15% at CER) to $1,671m. The new medicines
represented 34% of ex-China Emerging Markets Total Revenue in the
half (H1 2019: 27%), increasing by 39% (48% at CER) to $572m. The
performance was underpinned by strong levels of growth across the
following:
Table 15: Ex-China Emerging Markets: Total Revenue
|
|
H1 2020
|
Q2 2020
|
||||
|
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
|||
|
Ex-China Asia Pacific
|
597
|
5
|
7
|
286
|
(1)
|
2
|
|
Middle East and Africa
|
530
|
10
|
12
|
266
|
9
|
12
|
|
Ex-Brazil Latin America
|
206
|
(2)
|
14
|
98
|
(10)
|
11
|
|
Russia
|
175
|
57
|
67
|
91
|
45
|
68
|
|
Brazil
|
161
|
(6)
|
16
|
72
|
(6)
|
28
|
Financial performance
Table 16: Reported Profit and Loss - H1 2020
|
|
H1 2020
|
H1 2019
|
% change
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
|
Total Revenue
|
12,629
|
11,314
|
12
|
14
|
|
Product Sales
|
12,359
|
11,183
|
11
|
13
|
|
Collaboration Revenue
|
270
|
131
|
n/m
|
n/m
|
|
|
|
|
|
|
|
Cost of Sales
|
(2,404)
|
(2,192)
|
10
|
15
|
|
|
|
|
|
|
|
Gross Profit
|
10,225
|
9,122
|
12
|
14
|
|
Gross Profit Margin
|
80.5%
|
80.4%
|
-
|
-
|
|
|
|
|
|
|
|
Distribution Expense
|
(191)
|
(159)
|
20
|
25
|
|
% Total Revenue
|
1.5%
|
1.4%
|
-
|
-
|
|
R&D Expense
|
(2,777)
|
(2,622)
|
6
|
7
|
|
% Total Revenue
|
22.0%
|
23.2%
|
+1
|
+1
|
|
SG&A Expense
|
(5,354)
|
(5,457)
|
(2)
|
-
|
|
% Total Revenue
|
42.4%
|
48.2%
|
+6
|
+6
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
601
|
706
|
(15)
|
(13)
|
|
% Total Revenue
|
4.8%
|
6.2%
|
-1
|
-1
|
|
|
|
|
|
|
|
Operating Profit
|
2,504
|
1,590
|
57
|
58
|
|
Operating Profit Margin
|
19.8%
|
14.1%
|
+6
|
+6
|
|
|
|
|
|
|
|
Net Finance Expense
|
(588)
|
(632)
|
(7)
|
(7)
|
|
Joint Ventures and Associates
|
(20)
|
(59)
|
(66)
|
(63)
|
|
|
|
|
|
|
|
Profit Before Tax
|
1,896
|
899
|
n/m
|
n/m
|
|
|
|
|
|
|
|
Taxation
|
(408)
|
(229)
|
78
|
76
|
|
Tax Rate
|
22%
|
25%
|
|
|
|
|
|
|
|
|
|
Profit After Tax
|
1,488
|
670
|
n/m
|
n/m
|
|
|
|
|
|
|
|
EPS
|
$1.17
|
$0.56
|
n/m
|
n/m
|
Table 17: Reported Profit and Loss - Q2 2020
|
|
Q2 2020
|
Q2 2019
|
% change
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
|
Total Revenue
|
6,275
|
5,823
|
8
|
11
|
|
Product Sales
|
6,048
|
5,718
|
6
|
9
|
|
Collaboration Revenue
|
227
|
105
|
n/m
|
n/m
|
|
|
|
|
|
|
|
Cost of Sales
|
(984)
|
(1,063)
|
(7)
|
3
|
|
|
|
|
|
|
|
Gross Profit
|
5,291
|
4,760
|
11
|
13
|
|
Gross Profit Margin
|
83.7%
|
81.4%
|
+2
|
+1
|
|
|
|
|
|
|
|
Distribution Expense
|
(104)
|
(81)
|
29
|
37
|
|
% Total Revenue
|
1.7%
|
1.4%
|
-
|
-
|
|
R&D Expense
|
(1,389)
|
(1,356)
|
2
|
4
|
|
% Total Revenue
|
22.1%
|
23.3%
|
+1
|
+1
|
|
SG&A Expense
|
(2,635)
|
(2,943)
|
(10)
|
(8)
|
|
% Total Revenue
|
42.0%
|
50.6%
|
+9
|
+8
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
121
|
113
|
7
|
19
|
|
% Total Revenue
|
1.9%
|
2.0%
|
-
|
-
|
|
|
|
|
|
|
|
Operating Profit
|
1,284
|
493
|
n/m
|
n/m
|
|
Operating Profit Margin
|
20.5%
|
8.5%
|
+12
|
+11
|
|
|
|
|
|
|
|
Net Finance Expense
|
(307)
|
(320)
|
(4)
|
(5)
|
|
Joint Ventures and Associates
|
(16)
|
(32)
|
(50)
|
(45)
|
|
|
|
|
|
|
|
Profit Before Tax
|
961
|
141
|
n/m
|
n/m
|
|
|
|
|
|
|
|
Taxation
|
(223)
|
(34)
|
n/m
|
n/m
|
|
Tax Rate
|
23%
|
24%
|
|
|
|
|
|
|
|
|
|
Profit After Tax
|
738
|
107
|
n/m
|
n/m
|
|
|
|
|
|
|
|
EPS
|
$0.58
|
$0.09
|
n/m
|
n/m
|
Table 18: Reconciliation of Reported Profit Before Tax to EBITDA -
H1 2020
|
|
H1 2020
|
H1 2019
|
% change
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
|
Reported Profit Before Tax
|
1,896
|
899
|
n/m
|
n/m
|
|
Net Finance Expense
|
588
|
632
|
(7)
|
(7)
|
|
Joint Ventures and Associates
|
20
|
59
|
(66)
|
(63)
|
|
Depreciation, Amortisation and Impairment
|
1,551
|
1,403
|
11
|
12
|
|
|
|
|
|
|
|
EBITDA
|
4,055
|
2,993
|
35
|
37
|
Table 19: Reconciliation of Reported Profit Before Tax to EBITDA -
Q2 2020
|
|
Q2 2020
|
Q2 2019
|
% change
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
|
Reported Profit Before Tax
|
961
|
141
|
n/m
|
n/m
|
|
Net Finance Expense
|
307
|
320
|
(4)
|
(5)
|
|
Joint Ventures and Associates
|
16
|
32
|
(50)
|
(45)
|
|
Depreciation, Amortisation and Impairment
|
710
|
727
|
(2)
|
-
|
|
|
|
|
|
|
|
EBITDA
|
1,994
|
1,220
|
63
|
63
|
Table 20: Reconciliation of Reported to Core financial measures -
H1 202027
|
H1 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core
|
Core
% change
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
|
Gross Profit
|
10,225
|
35
|
33
|
-
|
5
|
10,298
|
12
|
13
|
|
Gross Profit Margin
|
80.5%
|
|
|
|
|
81.1%
|
-
|
-1
|
|
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(191)
|
-
|
-
|
-
|
-
|
(191)
|
20
|
25
|
|
R&D Expense
|
(2,777)
|
16
|
49
|
-
|
-
|
(2,712)
|
8
|
9
|
|
SG&A Expense
|
(5,354)
|
45
|
809
|
152
|
(5)
|
(4,353)
|
2
|
5
|
|
Total Operating Expenses
|
(8,322)
|
61
|
858
|
152
|
(5)
|
(7,256)
|
5
|
7
|
|
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
601
|
2
|
1
|
-
|
-
|
604
|
(15)
|
(13)
|
|
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
2,504
|
98
|
892
|
152
|
-
|
3,646
|
21
|
23
|
|
Operating Profit Margin
|
19.8%
|
|
|
|
|
28.9%
|
+2
|
+2
|
|
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(588)
|
-
|
-
|
115
|
104
|
(369)
|
(5)
|
(7)
|
|
Taxation
|
(408)
|
(20)
|
(183)
|
(60)
|
(1)
|
(672)
|
26
|
28
|
|
|
|
|
|
|
|
|
|
|
|
EPS
|
$1.17
|
$0.06
|
$0.54
|
$0.16
|
$0.08
|
$2.01
|
24
|
26
|
Table 21: Reconciliation of Reported to Core financial measures -
Q2 202028
|
Q2 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core
|
Core % change
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
|
Gross Profit
|
5,291
|
16
|
16
|
-
|
-
|
5,323
|
11
|
12
|
|
Gross Profit Margin
|
83.7%
|
|
|
|
|
84.3%
|
+2
|
+1
|
|
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(104)
|
-
|
-
|
-
|
-
|
(104)
|
29
|
37
|
|
R&D Expense
|
(1,389)
|
5
|
7
|
-
|
1
|
(1,376)
|
8
|
9
|
|
SG&A Expense
|
(2,635)
|
20
|
360
|
85
|
(6)
|
(2,176)
|
(1)
|
3
|
|
Total Operating Expenses
|
(4,128)
|
25
|
367
|
85
|
(5)
|
(3,656)
|
3
|
6
|
|
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
121
|
4
|
-
|
-
|
-
|
125
|
9
|
21
|
|
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
1,284
|
45
|
383
|
85
|
(5)
|
1,792
|
32
|
31
|
|
Operating Profit Margin
|
20.5%
|
|
|
|
|
28.6%
|
+5
|
+4
|
|
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(307)
|
-
|
-
|
58
|
49
|
(200)
|
1
|
(3)
|
|
Taxation
|
(223)
|
(9)
|
(76)
|
(29)
|
(1)
|
(338)
|
68
|
68
|
|
|
|
|
|
|
|
|
|
|
|
EPS
|
$0.58
|
$0.03
|
$0.23
|
$0.09
|
$0.03
|
$0.96
|
32
|
31
|
Profit and Loss summary
a)
Gross Profit
The
increases in Reported and Core Gross Profit in the half reflected
the growth in Product Sales. The Reported and Core Gross Profit
Margins were stable at 81%; the Core Gross Profit Margin declined
by one percentage point at CER, partly reflecting the impact of a
one-off change in estimate relating to Group inventory valuation
and the growth in profit share from the collaboration with MSD in
respect of Lynparza. The
Core Gross Profit Margin increased in the second quarter by two
percentage points (one at CER) to 84%, reflecting the mix of
Product Sales and manufacturing efficiencies.
b)
Total Operating Expense
Reported
Total Operating Expense increased by 1% in the half (3% at CER) to
$8,322m and represented 66% of Total Revenue (H1 2019: 73%).
Reported SG&A Expense was adversely impacted by an increased
level of intangible asset impairments, including a $102m charge
relating to Bydureon, and a
$96m charge relating to Eklira/Tudorza and Duaklir, partially offset by a $95m
impairment reversal in relation to FluMist. Core Total Operating Expense
increased by 5% (7% at CER) to $7,256m and represented 57% of Total
Revenue (H1 2019: 61%).
The
increases partly reflected investment in the pipeline, including
the development of Enhertu
and the ending in 2019 of the release of the upfront funding of
Lynparza development as
part of the agreement with
MSD; Core R&D Expense increased in the half by 8% (9% at CER)
to $2,712m. The increase in Core Total Operating Expense was also
driven by additional SG&A investment in Oncology-medicine
launches and AstraZeneca’s further expansion in China; Core
SG&A Expense increased in the half by 2% (5% at CER ) to
$4,353m.
c)
Other Operating Income and
Expense29
Reported
and Core Other Operating Income and Expense in the half included
$350m of income that reflected an agreement to
divest commercial rights to a number of legacy hypertension
medicines, as well as the divestment of the rights to Inderal, Tenormin, Seloken and Omepral in Japan for $51m. Income from
Allergan (part of AbbVie Inc) of $23m was also received in the half
in respect of the development of brazikumab.
d)
Net Finance Expense
The
declines in Reported and Core Net Finance Expense partly reflected
a favourable movement in loan interest, following the repayment of
a $1bn bond in 2019.
e)
Taxation
The
Reported and Core Tax Rates for the half were 22% and 21%
respectively (H1 2019: 25% and 21% respectively). The net cash tax
paid for the half was $792m, representing 42% of Reported Profit
Before Tax (H1 2019: $723m, 80%).
f)
EPS
Reported
EPS of $1.17 in the half represented an increase of 108% (106% at
CER); Core EPS increased by 24% (26% at CER) to $2.01. This was
despite an increase in the weighted-average number of shares to
1,312m (H1 2019: 1,289m).
g)
Dividends
The
Board has recommended an unchanged first interim dividend of $0.90
(69.6 pence, 7.87 SEK) per Ordinary Share.
Table 22: Cash Flow
|
|
H1 2020
|
H1 2019
|
Change
|
|
$m
|
$m
|
$m
|
|
|
Reported Operating Profit
|
2,504
|
1,590
|
914
|
|
Depreciation, Amortisation and Impairment
|
1,551
|
1,403
|
148
|
|
|
|
|
|
|
Increase in Working Capital and Short-Term Provisions
|
(780)
|
(634)
|
(146)
|
|
Gains on Disposal of Intangible Assets
|
(411)
|
(590)
|
179
|
|
Non-Cash and Other Movements
|
(555)
|
(177)
|
(378)
|
|
Interest Paid
|
(338)
|
(378)
|
40
|
|
Taxation Paid
|
(792)
|
(723)
|
(69)
|
|
|
|
|
|
|
Net Cash Inflow from Operating Activities
|
1,179
|
491
|
688
|
|
|
|
|
|
|
Net Cash Inflow/(Outflow) Before Financing Activities
|
1,336
|
(298)
|
1,634
|
|
|
|
|
|
|
Net Cash (Outflow)/Inflow from Financing Activities
|
(1,236)
|
941
|
(2,177)
|
The
increase in Net Cash Inflow from Operating Activities in the half
primarily reflected an underlying improvement in business
performance. The increase in Non-Cash and Other Movements of $378m
to $555m was driven by a reduction in fair-value movements on
business combination-related liabilities and included the effect of
the re-acquisition of US rights to Duaklir/Tudorza from Circassia Pharmaceuticals
plc (Circassia) in May 2020 in settlement of a loan receivable
balance included in working capital.
The
increase in Net Cash Inflow before Financing Activities was a
result of the aforementioned improvement in Net Cash Inflow from
Operating Activities, as well as a $931m increase in the Disposal
of Non-Current Asset Investments to $949m; AstraZeneca sold an
undisclosed proportion of its equity portfolio in the first half.
Recorded within the Purchase of Intangible Assets, AstraZeneca made
the second of two $675m upfront payments to Daiichi Sankyo as part
of the 2019 agreement on
Enhertu. There was a $313m
reduction in the Purchase of Intangible Assets, versus H1 2019, to
$983m.
The
cash payment of contingent consideration, in respect of the former
Bristol-Myers Squibb Company (BMS) share of the global diabetes
alliance, amounted to $257m in the half.
The
second interim dividend payment, amounting to $2,398m, was made in
the period.
Capital Expenditure
Capital
expenditure amounted to $370m in the half, compared to $438m in H1
2019. This included investment in the new AstraZeneca R&D
centre on the Biomedical Campus in Cambridge, UK; total capital
expenditure on the entire project to the end of June 2020 amounted
to $993m (£787m, based on average exchange rates). It is too
early to state the potential impact of ongoing COVID-19
restrictions and physical-distancing measures to the Cambridge
construction schedule and project expenditure. The Company has made
other progress on its transition to Cambridge, including the Anne
McLaren Building on the Cambridge Biomedical Campus. As of the end
of June 2020, over 3,300 colleagues were based in and around the
city.
The
Company anticipates a broadly stable level of total capital
expenditure in FY 2020 (FY 2019: $979m).
Table 23: Net Debt summary
|
|
At 30 Jun 2020
|
At 31 Dec 2019
|
At 30 Jun 2019
|
|
$m
|
$m
|
$m
|
|
|
Cash
and Cash Equivalents
|
5,673
|
5,369
|
5,428
|
|
Other
Investments
|
442
|
911
|
875
|
|
|
|
|
|
|
Cash and Investments
|
6,115
|
6,280
|
6,303
|
|
|
|
|
|
|
Overdrafts
and Short-Term Borrowings
|
(1,799)
|
(225)
|
(629)
|
|
Lease
Liabilities
|
(639)
|
(675)
|
(720)
|
|
Current
Instalments of Loans
|
(2,159)
|
(1,597)
|
(1,000)
|
|
Non-Current
Instalments of Loans
|
(15,150)
|
(15,730)
|
(17,355)
|
|
|
|
|
|
|
Interest-Bearing Loans and Borrowings
(Gross Debt)
|
(19,747)
|
(18,227)
|
(19,704)
|
|
|
|
|
|
|
Net
Derivatives
|
(18)
|
43
|
321
|
|
Net Debt
|
(13,650)
|
(11,904)
|
(13,080)
|
Net
Debt increased by $1,746m in the half, principally due to Net Cash
Inflow from Operating Activities of $1,179m being more than offset
by the payment of the second interim dividend of 2019 of $2,398m
(representing two thirds of the 2019 full year).
Details
of the committed undrawn bank facilities are disclosed within the
going-concern section of Note 1.
During
the half, there were no changes to the Company’s credit
ratings issued by Standard and Poor’s (long term: BBB+, short
term A-2) and Moody’s (long term: A3, short term
P-2).
Capital allocation
The
Board’s aim is to continue to strike a balance between the
interests of the business, financial creditors and the
Company’s shareholders. After providing for investment in the
business, supporting the progressive dividend policy and
maintaining a strong, investment-grade credit rating, the Board
will keep under review potential investment in immediately
earnings-accretive, value-enhancing opportunities.
Foreign exchange
The
Company’s transactional currency exposures on working-capital
balances, which typically extend for up to three months, are hedged
where practicable using forward foreign-exchange contracts against
the individual companies’ reporting currency.
Foreign-exchange gains and losses on forward contracts for
transactional hedging are taken to profit or loss. In addition, the
Company’s external dividend payments, paid principally in
pounds sterling and Swedish krona, are fully hedged from
announcement to payment date.
Table 24: Currency sensitivities
The
Company provides the following currency-sensitivity
information:
|
|
Average Exchange
Rates versus USD
|
|
Annual Impact of 5% Strengthening in Exchange Rate versus USD
($m)30
|
|||
|
Currency
|
Primary Relevance
|
FY 201931
|
H1 202032
|
% change
|
Product Sales
|
Core Operating Profit
|
|
CNY
|
Product
Sales
|
6.92
|
6.88
|
-
|
288
|
190
|
|
EUR
|
Product
Sales
|
0.89
|
0.93
|
(4)
|
171
|
68
|
|
JPY
|
Product
Sales
|
108.98
|
105.74
|
3
|
139
|
98
|
|
Other33
|
|
|
|
|
231
|
123
|
|
|
|
|
|
|
|
|
|
GBP
|
Operating
Expense
|
0.78
|
0.81
|
(4)
|
27
|
(93)
|
|
SEK
|
Operating
Expense
|
9.46
|
9.45
|
-
|
5
|
(51)
|
Related-party transactions
There
have been no significant related-party transactions in the
period.
Principal risks and uncertainties
It is
not anticipated that the nature of the principal risks and
uncertainties that affect the business (including the
Company’s scientific and operational response to the COVID-19
pandemic), and which are set out on pages 74 to 77 of the Annual
Report and Form 20-F Information 2019, will change in respect of
the second six months of the financial year. The impact of COVID-19
on AstraZeneca’s operations is highly uncertain and cannot be
predicted with confidence. The extent of any adverse impact on
AstraZeneca’s operations (including the effects of any
governmental or regulatory response to the pandemic) will depend on
the global duration, extent and severity of the pandemic. To the
extent the pandemic adversely affects AstraZeneca operations and/or
performance, the Company expects it to have the effect of
heightening certain risks, such as those relating to the delivery
of the pipeline or launch of new medicines, the execution of
AstraZeneca’s commercial strategy, the manufacturing and
supply of medicines and reliance on third-party goods and services.
The potential impact of Brexit continues to be treated as an
integral part of the Principal Risks rather than as a stand-alone
risk, as summarised on page 75 of the Annual Report and 20F
information 2019.
In
summary, the principal risks and uncertainties listed in the Annual
Report and 20-F Information 2019 are:
1.
Medicine pipeline
and intellectual property risks: failure or delay in delivery of
pipeline and new medicines; failure to meet regulatory or ethical
requirements for medicine development or approval; failure to
obtain, defend and enforce effective intellectual property (IP)
protection or IP challenges by third parties.
2.
Commercialisation
risks: pricing, affordability, access and competitive pressures;
failures or delays in quality execution of commercial
strategies.
3.
Supply-chain and
business-execution risks: failure to maintain supply of compliant,
quality medicines; failure of information technology and data
protection or cybercrime; failure to attract, develop, engage and
retain a diverse, talented and capable workforce.
4.
Legal, regulatory
and compliance risks: safety and efficacy of marketed medicines is
questioned; adverse outcome of litigation and / or governmental
investigations; failure to meet regulatory and ethical expectations
on commercial practices, including bribery and corruption, and
scientific exchanges.
5.
Economic and
financial risks: failure to achieve strategic plans or meet targets
or expectations.
Sustainability
AstraZeneca’s
sustainability approach has three priority areas34, aligned with the Company’s
purpose and business strategy:
-
Access to
healthcare
-
Environmental
protection
-
Ethics and
transparency
Recent
developments and progress against the Company’s priorities
are reported below:
a)
Access to healthcare
In
April 2020, AstraZeneca signed a licence, development and
distribution agreement with
the University of Oxford for AZD1222. The Company also made several
landmark agreements in the period, most notably, with BARDA and
parallel agreements with the UK Government, Europe’s IVA, and
CEPI, GAVI and the SII to supply low-and-middle-income
countries.
In May
2020, AstraZeneca achieved the support of more than $1bn from BARDA
for the development, production and delivery of the AZD1222
vaccine, starting in H2 2020. The development programme includes a
Phase III clinical trial, with c.30,000 participants.
In June
2020, the Company announced a $750m agreement with
CEPI and GAVI to support the manufacturing, procurement and
distribution of 300 million doses of the vaccine, with delivery
starting by the end of the year. Also, AstraZeneca reached a
licensing agreement with the SII to supply one billion doses for
low and middle-income countries, with a commitment to provide 400
million doses before the end of 2020. The agreement with CEPI and
GAVI also represented the first advanced market commitment through
the Access to COVID-19 Tools Accelerator, a global collaboration of
philanthropic, multi-lateral, private sector and civil society
partners.
The
Company also announced in June 2020 that it had reached an
agreement with
Europe's IVA, spearheaded by Germany, France, Italy and the
Netherlands, to supply up to 400 million doses of the vaccine. The
IVA aims to accelerate the supply of the vaccine and to make it
available to other European countries that wish to participate in
the initiative and is committed to providing equitable access to
all participating countries across Europe. In July 2020,
AstraZeneca announced agreements with R-Pharm in Russia and SK
Biopharmaceuticals Co., Ltd in the Republic of Korea to manufacture
and export for other global markets.
These
agreements marked the latest commitments to support broad and
equitable global access to the vaccine, particularly for low and
middle-income countries. In aggregate, these parallel agreements
have helped to provide a total manufacturing capacity of over two
billion doses of the vaccine at no profit to AstraZeneca during the
pandemic, in line with the aforementioned licence agreement with
the University of Oxford.
During
the period, AstraZeneca announced the signing of a Memorandum of
Understanding with the Ministry of Health (MoH) of the Republic of
Uganda for the expansion of the Company’s Healthy Heart
Africa programme. The agreement will make Uganda the fifth
country of implementation after Kenya, Ethiopia, Tanzania and
Ghana. The partnership aims to strengthen the provision of services
for managing and preventing hypertension, including raising
awareness of lifestyle risk factors for CV disease, using MoH
guidelines to standardise care, and upskilling health workers
through training and education.
b)
Environmental protection
In the
period, the Solutions Journal
published a 10-point action plan co-authored by Professor
Jason Snape, Head of Environmental Protection, Global
Sustainability, AstraZeneca. The action plan highlighted the
strategies required for a more sustainable future post-pandemic and
focused on the implementation of a circular bioeconomy. The article
reflected the work of the Sustainable Markets
Council, established by His Royal Highness, The Prince of
Wales in September 2019, of which AstraZeneca and Pascal Soriot are
founding council members.
In June
2020, The Prince of Wales launched The Great Reset
with the World Economic Forum, a new global and multi-stakeholder
call to action. The initiative will explore the necessary steps to
recalibrate global systems in a post-pandemic world for a future
that is more resilient, sustainable and inclusive. AstraZeneca
actively supports progress towards a circular bioeconomy and The
Great Reset as part of the Sustainable Markets Initiative and the
need to operate responsibly and sustainably in the post-COVID-19
recovery.
During
the period, Pascal Soriot was one of 176 business
leaders13
from member companies of the Science-Based Targets
initiative that signed a statement
urging governments around the world to align their COVID-19
economic aid and recovery efforts with the latest climate science,
which was announced by the
UNGC in May 2020.
c)
Ethics and transparency
Further
highlighting the Company’s commitment to inclusion and
diversity, AstraZeneca was recognised by DiversityInc as
one of the 2020 Top 50 Companies
for Diversity and the Company was also named as a Top
Company for LGBT employees. In further recognition, Caireen
Hargreaves, Associate Director, Product Sustainability,
AstraZeneca, was awarded a position in the 2020 Top 50 Women in
Engineering - Sustainability by the UK’s Women’s
Engineering Society.
In July
2020, an interview was
published by Reuters with AstraZeneca’s Executive Vice
President, Human Resources, Fiona Cicconi. This focused on the
additional measures implemented by the Company to support employees
impacted by COVID-related gaps in children’s education and
care provision. Measures included recruiting up to 80 teachers to
run online lessons, providing personal tutoring and helping to
locate some childcare spaces to ensure employees are able to focus
and continue to develop and deliver life-changing
medicines.
During
the period, Heather Stewart, Vice President, Ethics
& Transparency and Deputy Chief Compliance Officer, Global
Sustainability spoke at a UNGC Deep Dive Insights kick-off webinar,
as part of Workstream II Putting a Human Face to Climate Change of
the Business Ambition for
Climate and Health Action Platform, where the Company is
Patron sponsor, which is developing a Human Rights Impact Guide for
companies.
For
more details on AstraZeneca’s sustainability ambition,
approach and targets, please refer to the latest Sustainability Report
2019 and Sustainability Data
Summary 2019. Additional information is available at
astrazeneca.com/sustainability.
Research and development
As the
COVID-19 pandemic develops, the Company will evaluate the impact on
the initiation of clinical trials, ongoing recruitment and
follow-ups. It is prudent to assume that some delays will arise as
a consequence of the pandemic.
A
comprehensive breakdown of AstraZeneca’s pipeline of
medicines in human trials can be found in the latest
clinical-trials appendix, available on astrazeneca.com.
Highlights of developments in the Company’s late-stage
pipeline since the prior results announcement are shown
below:
Table 25: Late-stage pipeline
|
New
molecular entities and major lifecycle events for medicines in
Phase III trials or under regulatory review
|
17
|
Oncology
- Tagrisso - NSCLC
- Imfinzi - multiple cancers
-
Lynparza - multiple
cancers
- Enhertu - multiple cancers
- capivasertib -
breast cancer
- Calquence - blood cancers
- tremelimumab -
multiple cancers
CVRM
- Farxiga - multiple
indications
- roxadustat -
anaemia in CKD
Respiratory & Immunology
- Fasenra - multiple
indications
- PT010 -
COPD
- PT027 -
asthma
- tezepelumab -
severe asthma
- nirsevimab -
respiratory syncytial virus
- anifrolumab - lupus
(SLE)
- brazikumab -
inflammatory bowel disease43
|
|
Total
projects
in
clinical pipeline
|
142
|
|
Oncology
During
the period, AstraZeneca presented new results across its broad
portfolio of cancer medicines at the 2020 American Society of
Clinical Oncology (ASCO20) Virtual Scientific Program, comprising
98 abstracts, including 19 oral presentations with one plenary and
10 late-breakers.
Presentations
demonstrated the Company’s leadership in the treatment of
early lung cancer, reflected by a late-breaking plenary
presentation of the unprecedented results from the Phase III ADAURA
trial for Tagrisso in the
adjuvant treatment of patients with Stage IB, II and IIIA EGFRm
NSCLC. Detailed results from an updated analysis of the Phase III
CASPIAN trial were also presented where Imfinzi, in combination with a choice
of chemotherapies, demonstrated a sustained, clinically meaningful
overall survival (OS) benefit in ES-SCLC. Data from the DESTINY
programme highlighted the potential of Enhertu across HER2-driven tumours,
including lung, breast, gastric and colorectal
cancers.
Oncology: lung cancer
a)
Tagrisso
During
the ASCO20 Virtual Scientific Program, detailed results from the
Phase III ADAURA trial were presented in a plenary session.
Tagrisso demonstrated a
statistically significant and clinically meaningful improvement in
disease-free survival (DFS) in the adjuvant treatment of patients
with early-stage (IB, II and IIIA) EGFRm NSCLC after complete
tumour resection with curative intent. For the primary endpoint of
DFS in patients with Stage II and IIIA disease, adjuvant treatment
with Tagrisso reduced the
risk of disease recurrence or death by 83% (hazard ratio [HR] 0.17;
95% confidence interval (CI) 0.12-0.23; p<0.0001). DFS results
in the overall trial population, Stage IB through IIIA, a key
secondary endpoint, demonstrated a reduction in the risk of disease
recurrence or death of 79% (HR 0.21; 95% CI 0.16-0.28;
p<0.0001). Consistent DFS results were seen across all
subgroups, including patients who were treated with surgery
followed by chemotherapy and those who received surgery only, as
well as in Asian and non-Asian patients.
Table 26: Key Tagrisso
trials in lung cancer
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
|
Phase
III
NeoADAURA
|
Neo-adjuvant
EGFRm
NSCLC
|
Placebo
or Tagrisso
|
FPCD39
Q2
2020
First
data anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
ADAURA
|
Adjuvant
EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2015
LPCD40
Q1
2019
|
Trial
unblinded early due to overwhelming efficacy
|
|
Phase
III
LAURA
|
Locally
advanced, unresectable EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
FLAURA2
|
1st-line
EGFRm NSCLC
|
Tagrisso or Tagrisso
+ platinum-based chemotherapy doublet
|
FPCD
Q4
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
b)
Imfinzi
Detailed
results from an updated analysis of the Phase III CASPIAN
Imfinzi trial were
presented at the ASCO20 Virtual Scientific Program. Imfinzi, in combination with a choice
of chemotherapies, etoposide plus either carboplatin or cisplatin,
demonstrated a sustained, clinically meaningful OS benefit for
adults with ES-SCLC. The CASPIAN trial had previously met the
primary endpoint of OS in June 2019, which formed the basis of the
US FDA approval in March 2020.
After a
median follow-up of more than two years, the latest results for
Imfinzi plus chemotherapy
showed sustained efficacy, maintaining a 25% reduction in the risk
of death versus chemotherapy alone (HR 0.75; 95% CI 0.62-0.91;
nominal p=0.0032). Updated median OS was 12.9 months, versus 10.5
for chemotherapy.
During
the period, the Company announced that Imfinzi had been recommended for
marketing authorisation in the EU for the 1st-line treatment of
adults with ES-SCLC in combination with a choice of chemotherapies,
etoposide plus either carboplatin or cisplatin. The Committee for
Medicinal Products for Human Use41 (CHMP) based its positive opinion on
results from the Phase III CASPIAN trial for Imfinzi plus chemotherapy, which were
also published in The
Lancet.
Table 27: Key Imfinzi
trials in lung cancer
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
|
Phase
III
MERMAID-1
|
Stage
II-III
resected
NSCLC
|
SoC
chemotherapy +/- Imfinzi
|
-
First
data anticipated
2021+
|
Initiating
|
|
Phase
III
AEGEAN
|
Neo-adjuvant
(before surgery) NSCLC
|
SoC
chemotherapy +/- Imfinzi,
followed
by
surgery,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
ADJUVANT
BR.3142
|
Stage
Ib-IIIa NSCLC
|
Placebo or
Imfinzi
|
FPCD
Q1
2015
LPCD
Q1
2020
First
data anticipated
2021+
|
Recruitment
completed
|
|
Phase
III
PACIFIC-2
|
Stage
III unresected locally advanced NSCLC
(concurrent
CRT)
|
Placebo or
Imfinzi
|
FPCD
Q2
2018
LPCD
Q3
2019
First
data anticipated
H2
2020
|
Recruitment
completed
|
|
Phase
III
ADRIATIC
|
Limited-
stage
SCLC
|
Concurrent
CRT,
followed
by
placebo
or
Imfinzi or Imfinzi +
treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
PEARL
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or Imfinzi
|
FPCD
Q1
2017
LPCD
Q1
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
|
Phase
III
POSEIDON
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or SoC +
Imfinzi or SoC +
Imfinzi +
treme
|
FPCD
Q2
2017
LPCD
Q4
2018
OS data
anticipated
H2
2021
|
PFS43
primary endpoint met
|
|
Phase
III
CASPIAN
|
ES-SCLC
|
SoC
chemotherapy or SoC +
Imfinzi or SoC +
Imfinzi +
treme
|
FPCD
Q1
2017
LPCD
Q2
2018
|
OS
primary endpoint met for Imfinzi monotherapy arm
OS
primary endpoint not met for Imfinzi + treme
|
As a
result of the positive Tagrisso ADAURA Phase III trial in the
adjuvant treatment of EGFRm NSCLC, the impact on the Imfinzi ADJUVANT BR.31 Phase III trial
analysis plan is currently being reviewed; data from this trial is
anticipated in 2021+.
Table 28: Key Imfinzi
trials in tumour types other than lung cancer
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
|
Phase
III
POTOMAC
|
Non-muscle
invasive bladder cancer
|
SoC
BCG44 or SoC BCG + Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
NIAGARA
|
Muscle-invasive
bladder cancer
|
Neo-adjuvant
cisplatin and gemcitabine SoC chemotherapy or SoC + Imfinzi, followed by adjuvant placebo
or Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
|
Phase
III
EMERALD-1
|
Locoregional
HCC45
|
TACE46
followed by placebo or TACE + Imfinzi, followed by Imfinzi +
bevacizumab
or
TACE +
Imfinzi
followed
by Imfinzi
|
FPCD
Q1
2019
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
|
Phase
III
EMERALD-2
|
Locoregional
HCC at high risk of recurrence after surgery or radiofrequency
ablation
|
Adjuvant
Imfinzi or Imfinzi + bevacizumab
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
CALLA
|
Locally
advanced cervical cancer
|
CRT or
CRT + Imfinzi, followed by
placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
NILE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible bladder
cancer
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
KESTREL
|
Stage
IV, 1st-line HNSCC47
|
SoC or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
H1
2021
|
Recruitment
completed
|
|
Phase
III
HIMALAYA
|
Stage
IV, 1st-line unresectable HCC
|
Sorafenib or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2017
LPCD
Q4
2019
First
data
anticipated
H2
2020
|
Recruitment
completed
Orphan
Drug Designation (US)48
|
|
Phase
III
TOPAZ-1
|
Stage
IV, 1st-line biliary-tract cancer
|
Gemcitabine
and cisplatin SoC chemotherapy or SoC + Imfinzi
|
FPCD
Q2
2019
First
data anticipated
H2
2021
|
Recruitment
ongoing
|
c)
Lynparza
(multiple
cancers)
During the period, AstraZeneca announced that Lynparza, in combination with bevacizumab, was approved in
the US for the maintenance treatment of platinum-sensitive ovarian
cancer patients whose cancer is associated with HRD-positive
status. The approval by the US FDA was based on a subgroup analysis
of the Phase III PAOLA-1 trial, which showed that
Lynparza, in combination with bevacizumab maintenance
treatment, reduced the risk of disease progression or death by 67%
(equal to a hazard ratio of 0.33). The addition of
Lynparza
improved progression-free survival
(PFS) to a median of 37.2 months, versus 17.7 months with
bevacizumab alone in patients with HRD-positive advanced ovarian
cancer.
During the period, AstraZeneca also announced that
Lynparza
had received regulatory approval in
the US for patients with HRR gene-mutated metastatic
castration-resistant prostate cancer (mCRPC). The approval was
based on results from the Phase III PROfound trial, which were
published in The
New England Journal of Medicine. Lynparza demonstrated a radiographic PFS (rPFS) benefit in
the overall HRR gene-mutated trial population, a key secondary
endpoint, and reduced the risk of disease progression or death by
51% (equal to a hazard ratio of 0.49; p-value <0.0001) and
improved rPFS to a median of 5.8 months, versus 3.5 months with
enzalutamide or abiraterone.
Additional
results from the PROfound trial, announced in April 2020,
demonstrated a statistically significant and clinically meaningful
improvement in the key secondary endpoint of OS with Lynparza versus enzalutamide or
abiraterone in men with mCRPC and BRCA1/2 or Ataxia-Telangiectasia
Mutated gene mutations. Results showed that Lynparza reduced the risk of death by
31% (equal to a hazard ratio of 0.69; p-value=0.0175) and improved
OS to a median of 19.0 months, versus 14.6 months with enzalutamide
or abiraterone.
During the period, the Company announced that Lynparza had been approved in the EU for patients with
germline BRCAm (gBRCAm) metastatic pancreatic cancer, based on
results from the Phase III POLO trial. The trial demonstrated
that Lynparza nearly doubled the time patients with gBRCAm
metastatic pancreatic cancer lived without disease progression or
death to a median of 7.4 months, versus 3.8 months on
placebo.
Table 29: Key Lynparza
trials
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
|
Phase
III
OlympiA
|
Adjuvant
BRCAm breast cancer
|
SoC
placebo or Lynparza
|
FPCD
Q2
2014
LPCD
Q2
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
|
Phase
III
PROfound
|
Metastatic
castration-resistant 2nd-line+ HRRm
prostate
cancer
|
SoC
(abiraterone or enzalutamide) or Lynparza
|
FPCD
Q2
2017
LPCD
Q4
2018
|
Primary
endpoint met
Priority
Review (US)
|
|
Phase
III
PAOLA-149
|
Advanced
1st-line
ovarian
cancer
|
Bevacizumab
maintenance or
bevacizumab
+
Lynparza maintenance
|
FPCD
Q2
2015
LPCD
Q2
2018
|
Primary
endpoint met
Priority
Review (US)
|
|
Phase
II/III
GY005
|
Recurrent
platinum-resistant/refractory ovarian cancer
|
SoC
chemotherapy or cediranib or cediranib + Lynparza
|
FPCD
Q2
2016
(Phase
II)
FPCD
Q1
2019
(Phase
III)
First
data
anticipated
2021+
|
Recruitment
ongoing
(Phase
III component)
|
|
Phase
III
DuO-O
|
Advanced
1st-line
ovarian
cancer
|
Chemotherapy
+
bevacizumab
or
chemotherapy
+
bevacizumab
+
Imfinzi +/-
Lynparza maintenance
|
FPCD
Q1 2019
First
data
anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
DuO-E
|
Advanced
1st-line
endometrial
cancer
|
Chemotherapy
or
chemotherapy
+
Imfinzi + Imfinzi
maintenance or
chemotherapy
+
Imfinzi followed by Imfinzi + Lynparza maintenance
|
FPCD
Q2 2020
First
data
anticipated
2021+
|
Recruitment
ongoing
|
|
Phase
III
PROpel
|
Stage
IV, advanced, castration-resistant prostate cancer
|
Abiraterone
or
abiraterone
+
Lynparza
|
FPCD
Q4
2018
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
|
Phase
III
LYNK-003
|
Stage
IV, 1st-line colorectal cancer
|
Bevacizumab
+ 5-FU maintenance or bevacizumab + Lynparza maintenance or Lynparza maintenance
|
First
data
anticipated
2021+
|
Initiating
|
d)
Enhertu
(breast and other
cancers)
During
the period, the regulatory submission for Enhertu was accepted in the EU for the
treatment of adults with unresectable or metastatic HER2-positive
breast cancer who have received two or more prior anti-HER2 based
regimens. Enhertu was
granted accelerated assessment by the CHMP. Daiichi Sankyo also
announced a supplemental New Drug Application with expedited review
by the Japan Ministry of Health, Labour and Welfare, based on
SAKIGAKE-designation for Enhertu for the treatment of patients
with HER2-positive metastatic gastric cancer.
During
the period, key Enhertu
data were presented at the ASCO20 Virtual Scientific Program in
gastric cancer. Results from the positive, registrational,
randomised controlled Phase II DESTINY-Gastric01 trial showed
Enhertu demonstrated a
statistically significant and clinically meaningful improvement in
the objective response rate (ORR) of 42.9% and OS, a key secondary
endpoint with a HR of 0.59 (95% CI 0.39-0.88; p=0.0097) versus
chemotherapy. During the period, the US FDA awarded Breakthrough
Therapy Designation to Enhertu for HER2-positive metastatic
gastric cancer.
Enhertu also had results in lung and colorectal cancer at
the ASCO20 Virtual Scientific Program. In lung cancer, data from
the ongoing Phase II DESTINY-Lung01 trial showed Enhertu achieved a clinically
meaningful tumour response in patients with HER2m unresectable
and/or metastatic non-squamous NSCLC, whose disease had progressed
following one or more systemic therapies with an ORR, assessed by
independent central review of 61.9%. In colorectal cancer at the
same meeting, results from the Phase II DESTINY-CRC01 trial
demonstrated clinically meaningful activity in patients with
HER2-positive unresectable and/or metastatic colorectal cancer who
had received at least two prior lines of standard treatment, with
45.3% of patients achieving a tumour response. During the period,
the US FDA awarded Breakthrough Therapy Designation to Enhertu for HER2m lung
cancer.
Table 30: Key Enhertu
trials
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
|
Phase
II
DESTINY-Breast01
|
Stage
IV, HER2+50 breast cancer post trastuzumab
emtansine
|
Enhertu
(single
arm)
|
FPCD
Q4
2017
LPCD
Q4
2018
|
Primary
objective met
Breakthrough
Therapy Designation (US)
Approval
(JP), Accelerated Approval (US)
|
|
Phase
III
DESTINY-Breast02
|
Stage
IV, HER2+ breast cancer post trastuzumab emtansine
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
H2
2021
|
Recruitment ongoing
|
|
Phase
III
DESTINY-Breast03
|
Stage
IV, HER2+ breast cancer
|
Trastuzumab
emtansine or Enhertu
|
FPCD
Q4
2018
First
data anticipated
H2
2021
|
Recruitment ongoing
|
|
Phase
III
DESTINY-Breast04
|
Stage
IV, HER2-low
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
H2
2021
|
Recruitment ongoing
|
|
Phase
II
DESTINY-Gastric01
|
Stage
IV, HER2+ gastric cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2017
LPCD
Q2
2019
|
Primary
endpoint met
US
Breakthrough Therapy Designation
|
|
Phase
II
DPT02
|
HER2-expressing
tumours
|
Enhertu
|
-
|
Initiating
|
e)
Calquence
During
the period, Calquence was
recommended for marketing authorisation in the EU for the treatment
of adult patients with CLL. The CHMP based its positive opinion on
results from two Phase III clinical trials, ELEVATE TN in patients
with previously untreated CLL, and ASCEND in patients with relapsed
or refractory CLL.
f)
Koselugo
(NF1)
During
the period, the Company announced that Koselugo (formerly selumetinib) was
granted orphan drug designation in Japan for the treatment of NF1,
following results from the Phase II SPRINT trial which demonstrated
that Koselugo reduced
tumour volume in paediatric patients with NF1 plexiform
neurofibromas.
g)
New collaboration to develop and commercialise new antibody drug
conjugate
In July
2020, the Company announced that it had entered into a new global
development and commercialisation agreement with Daiichi Sankyo for
DS-1062, its proprietary trophoblast cell-surface antigen 2
(TROP2)-directed antibody drug conjugate and potential new medicine
for the treatment of multiple tumour types. DS-1062 is currently in
development for the treatment of multiple tumours that commonly
express the cell-surface glycoprotein TROP2. Among them, TROP2 is
overexpressed in the majority of NSCLCs and breast cancers that
have long been a strategic focus for AstraZeneca. The collaboration
reflects AstraZeneca’s strategy to invest in antibody drug
conjugates as a class, the innovative nature of the technology and
the successful existing collaboration with Daiichi
Sankyo.
h)
Savolitinib (lung cancer)
During
the period, Hutchison China MediTech Limited announced that the
NMPA has granted Priority Review status to the new drug application
for savolitinib for the treatment of NSCLC with MET Exon 14
skipping mutations. As per the original agreement announced in
2011, AstraZeneca will manufacture and commercialise
savolitinib.
i)
FKB238: bevacizumab biosimilar - (multiple cancers)
During
the period, Centus Biotherapeutics Ltd., a joint venture between
AstraZeneca and Fujifilm Kyowa Kirin Biologics Co., Ltd, announced
that the CHMP had adopted a positive opinion for the Marketing
Authorisation Application of FKB238, the companies’ Avastin
bevacizumab biosimilar, for indications including metastatic
carcinoma of the colon or rectum, metastatic breast cancer,
unresectable advanced, metastatic or recurrent NSCLC, advanced
and/or metastatic renal cell cancer, epithelial ovarian, fallopian
tube, or primary peritoneal cancer, and persistent, recurrent, or
metastatic carcinoma of the cervix.
CVRM
During the period, AstraZeneca presented new data from the Phase
III DAPA-HF and DECLARE-TIMI 58 trials at the American Diabetes
Association Virtual Conference. The data were among 23 accepted
abstracts, including four oral presentations, covering trials
across the Company’s cardio, renal and metabolic
portfolio.
In June 2020, AstraZeneca presented new data across its broad
portfolio of renal medicines at the 57th European Renal Association
- European Dialysis and Transplant Association (ERA-EDTA) Virtual
Congress. The 20 abstracts presented, included four oral
presentations for Lokelma, roxadustat and Farxiga, respectively, across different stages of
CKD.
a)
Farxiga
(chronic kidney disease
and heart failure)
In March 2020, the Company announced that the DAPA-CKD trial, which
evaluated Farxiga in CKD, was stopped early due to overwhelming
efficacy. In July 2020, AstraZeneca announced that the trial showed
a statistically significant and clinically meaningful effect on its
primary endpoint of a composite of worsening of renal function or
risk of death (defined as a composite endpoint of ≥50%
sustained decline in estimated glomerular filtration rate (eGFR),
onset of end-stage renal disease (ESRD) or CV or renal death) in adult patients
with CKD. The trial also met all its secondary endpoints in CKD
patients with and without T2D, making Farxiga the first medicine to significantly reduce the
risk of death from any cause in this patient population. The full
DAPA-CKD trial results will be presented at a forthcoming medical
meeting.
In May 2020, the Company announced that the US FDA had
approved Farxiga to reduce the risk of CV death and hospitalisation
for HF in adults with HF (New York Heart Association class II-IV)
with reduced ejection fraction with and without T2D. The approval
was based on positive results from the landmark Phase
III DAPA-HF trial, which showed Farxiga achieving a statistically
significant and clinically meaningful reduction of CV death or
hospitalisation for HF, compared to placebo.
In July
2020, the Company announced that the US FDA had granted Fast Track
Designation for the development of Farxiga to reduce the risk of
hospitalisation for heart failure or cardiovascular death in adults
following an acute myocardial infarction (MI) or heart attack. The
designation is based on the Phase III DAPA-MI trial that will
explore the efficacy and safety of Farxiga in this patient population and
is the first indication-seeking registry-based randomised
controlled trial. The trial is expected to begin recruiting in the
fourth quarter of 2020.
b)
Brilinta
(heart disease and
stroke)
During
the period, the US FDA approved Brilinta to reduce the risk of a first
heart attack or stroke in high-risk patients with CAD,
the most common type of heart disease. The approval was based
on positive results from the Phase III THEMIS trial. The Company
also decided to stop the HESTIA3 trial, which evaluated
Brilinta for the prevention
of vaso-occlusive crises in paediatric patients with sickle-cell
disease. The decision was based on a recommendation from an
Independent Data Monitoring Committee (IDMC), due to a low likelihood of
demonstrating benefits that outweigh the risks.
In July
2020, the Company announced that the US FDA had accepted a
supplemental New Drug Application and granted Priority Review
designation for Brilinta
for the reduction of subsequent stroke in patients who experienced
an acute ischemic stroke or transient ischemic attack. The PDUFA
date is set for the fourth quarter of 2020. The Priority Review
designation was based on data from the Phase III THALES trial.
During the period, the Company also received regulatory submission
acceptance in the EU for the same indication.
The
full results from the THALES trial were published in The New England Journal of Medicine in
July, showing that Brilinta
90mg used twice daily and taken with daily aspirin for 30 days,
reduced the rate of the primary composite endpoint of stroke and
death by 17% (HR 0.83 [95% CI 0.71-0.96], p=0.02), compared to
aspirin alone in patients who had an acute ischemic stroke or
transient ischemic attack.
Table 31: Key large CVRM outcomes trials
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
|
Farxiga
|
|
||||
|
Phase
III
DAPA-HF
|
c.4,500
patients with HF with reduced ejection fraction, with and without
T2D
|
Arm 1:
Farxiga 10mg or 5mg
QD51 + SoC
Arm 2:
placebo + SoC
|
Time to
first occurrence of CV death or hospitalisation due to HF or an
urgent HF visit
|
FPCD
Q1
2017
LPCD
Q4
2018
|
Primary
endpoint met
Fast
Track designation (US)
|
|
Phase
III
DELIVER
|
c.4,700
patients with HF and preserved ejection fraction, with and without
T2D
|
Arm 1:
Farxiga 10mg
QD
Arm 2:
placebo
|
Time to
first occurrence of CV death or worsening HF
|
FPCD
Q4
2018
First
data anticipatedH2 2021
|
Recruitment
ongoing
Fast
Track designation (US)
|
|
Phase
III
DAPA-CKD
|
c.4,000
patients with CKD, with and without T2D
|
Arm 1:
Farxiga 10mg or 5mg
QD
Arm 2:
placebo
|
Time to
first occurrence of ≥ 50% sustained decline in eGFR or
reaching ESRD or CV death or renal death
|
FPCD
Q1
2017
LPCD
Q1
2020
|
Trial
stopped early based on recommendation from an IDMC
Primary
endpoint and secondary endpoints met
Fast
Track designation (US)
|
|
Brilinta
|
|
||||
|
Phase
III THEMIS
|
c.19,000
patients with T2D and CAD without a history of MI or
stroke
|
Arm 1:
Brilinta 60mg
BID52
Arm 2:
placebo BID on a background of aspirin if not
contra-indicated53 or not tolerated
|
Composite
of CV death, non-fatal MI and non-fatal stroke
|
FPCD
Q1
2014
LPCD
Q2
2016
|
Primary
endpoint met
|
|
Phase
III
THALES
|
c.11,000
patients with acute ischaemic stroke or transient ischaemic
attack
|
Arm 1:
Brilinta 90mg
BID
Arm 2:
placebo BID on a background of aspirin if not contra-indicated or
not tolerated
|
Prevention
of the composite of subsequent stroke and death at 30
days
|
FPCD
Q1
2018
LPCD
Q4
2019
|
Primary
endpoint met
Fast
Track
designation
(US)
|
c)
Roxadustat (anaemia)
Roxadustat
is currently undergoing US FDA review, with an anticipated
regulatory decision expected at the end of this year. During the
period, the US Institute for Clinical and Economic Review (ICER),
an independent non-profit research institute that produces reports
analysing the evidence on the effectiveness and value of medicines
and other medical services, announced that it will assess the
comparative clinical effectiveness and value of roxadustat for
treatment of anaemia in CKD. The assessment is anticipated to be
publicly discussed during a meeting of the California Technology
Assessment Forum in February 2021, where the independent evidence
review panel will deliberate and vote on evidence presented in
ICER’s report.
In June
2020, FibroGen and Astellas presented data at the ERA-EDTA Virtual
Congress from the Phase III DOLOMITES trial, which evaluated the
efficacy and safety of roxadustat compared to darbepoetin alfa for
the treatment of anaemia in NDD patients with Stage 3-5 CKD. In the
primary endpoint analysis, the trial demonstrated non-inferiority
of roxadustat compared to darbepoetin alfa in the proportion of
patients achieving correction of haemoglobin (Hb) levels during the
first 24 weeks of treatment (89.5% vs 78.0%; a difference of 11.51%
[95% CI 5.66%-17.36%]), with a lower bound of 95% CI >0%. The
response in correction of haemoglobin levels was defined as
achieving Hb ≥11g/dL and Hb increase from baseline of
≥1g/dL with baseline Hb >8g/dL, or Hb increase from
baseline of ≥2.0 g/dL in patients with baseline Hb ≤8.0
g/dL.
FibroGen
and AstraZeneca have made a number of regulatory submissions in RoW
countries, including Australia, Brazil, Canada, Chile, India,
Mexico, Philippines, Singapore, South Korea, Taiwan. FibroGen and
Astellas have received a regulatory approval in DD, and a
regulatory submission acceptance for NDD in Japan, while in Europe,
the FibroGen and Astellas received a regulatory submission
acceptance from the EMA in May 2020.
Respiratory & Immunology
a)
Bevespi
(COPD)
In May
2020, Bevespi was approved
in China as a maintenance treatment to relieve symptoms in patients
with COPD, including chronic bronchitis and/or emphysema. The
approval by the NMPA was based on positive results from the Phase
III PINNACLE 4 trial in which Bevespi demonstrated a statistically
significant improvement in lung function as measured by trough
forced expiratory volume in one second, compared to its monotherapy
components and placebo, all administered twice daily via
pressurised metered-dose inhaler in patients with moderate to very
severe COPD. The trial formed part of the broader PINNACLE clinical
trials programme showing efficacy and safety and involving more
than 5,000 patients across Asia, Europe and the
US.
b)
Breztri
(COPD)
In July
2020, AstraZeneca announced that the US FDA had approved
triple-combination therapy Breztri for the maintenance treatment of patients with
COPD. The approval was based on positive results from the Phase III
KRONOS and ETHOS trials.
During
the period, results from the positive Phase III ETHOS trial showed
that Breztri demonstrated a
statistically significant reduction in the rate of moderate or
severe exacerbations, compared with two dual-combination therapies,
in patients with moderate to very severe COPD. Compared with
Bevespi, Breztri achieved a 24% reduction
(p<0.001) in exacerbations; it also achieved a 13% reduction
(p=0.003) compared with PT009. The dual-combination therapies used
as comparators in the trial represented recommended therapeutic
classes for the treatment of COPD. In
a key secondary endpoint, Breztri showed a 46% reduction in the risk of all-cause
mortality compared with Bevespi (95% CI 13%-66%).
The
results were recently published in The New
England Journal of Medicine and simultaneously presented at
the American Thoracic Society Virtual Scientific Symposium.
AstraZeneca will continue to review these data with health
authorities.
c)
PT027 (asthma)
PT027
is a potential first-in-class fixed-dose combination of budesonide,
an ICS, and albuterol, a short-acting beta2 agonist. The Phase III
programme is evaluating its use in all severities of asthma from
four years of age as a rescue treatment. During the period, as a
result of the COVID-19 pandemic, enrolment of new patients into the
Phase III clinical development programme was paused in
collaboration with co-development partner, Avillion LLP.
Recruitment has since restarted, and data readouts are now
anticipated in 2021.
d)
Fasenra
(eosinophil-driven
diseases)
Table 32: Key Fasenra
lifecycle management trials
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
|
Phase
III OSTRO
|
Patients
(aged 18-75 years) with severe bilateral nasal polyposis;
symptomatic, despite SoC
|
Nasal-polyposis
burden and reported nasal blockage
|
FPCD
Q1
2018
LPCD
Q2
2019
Data
anticipated
H2
2020
|
Recruitment
completed
|
|
|
Phase
III RESOLUTE
|
Patients
with moderate to very severe COPD with a history of frequent COPD
exacerbations and elevated peripheral blood
eosinophils
|
Placebo
or Fasenra 100mg Q8W
SC
|
Annualised
rate of moderate or severe COPD exacerbations
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
|
|
Phase
III
MANDARA
|
Eosinophilic
granulomatosis with polyangiitis56
|
Fasenra 30mg or
mepolizumab
3x100mg Q4W57
|
Proportion
of patients who achieve remission, defined as a score58 =0 and an OCS dose ≤4 mg/day at
weeks 36 and 48
|
FPCD
Q4
2019
Data
anticipated
2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
|
Phase
III
NATRON
|
HES59
|
Placebo
or Fasenra 30mg Q4W
SC
|
Time to
HES worsening flare or any cytotoxic and/or immuno-suppressive
therapy increase or hospitalisation
|
FPCD
Q3
2020
Data
anticipated 2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
|
Phase
III
MESSINA
|
Eosinophilic
oesophagitis60
|
Placebo
or Fasenra 30mg Q4W
SC
|
Proportion
of patients with a histologic response
Changes
from baseline in dysphagia PRO61
|
Data
anticipated 2021+
|
Initiating
Orphan
Drug Designation (US)
|
|
Phase
III
FJORD
|
BP
|
Placebo
or Fasenra 30mg Q4W
SC
|
Proportion
of patients with partial or
complete
remission of BP whilst off OCS for ≥2 months
at Week
36
|
Data
anticipated 2021+
|
Initiating
|
d)
Tezepelumab (severe asthma)
During
the period, Amgen Inc (Amgen) and AstraZeneca updated the
2012
collaboration agreement for tezepelumab. Under the amended
agreement in the US, Amgen and AstraZeneca will jointly
commercialise tezepelumab and Amgen will record sales in the US.
AstraZeneca’s share of gross profits from tezepelumab in the
US will be recognised as Collaboration Revenue. In Canada, Amgen
and AstraZeneca will also jointly commercialise tezepelumab. In all
territories outside the US and Canada, AstraZeneca will solely
commercialise tezepelumab. AstraZeneca will record all sales
outside of the US as Product Sales.
Other
terms of clinical development and manufacturing remain unchanged.
AstraZeneca continues to lead clinical development and Amgen
continues to lead manufacturing. All aspects of the programme are
under the oversight of joint governing bodies. Both companies will
continue to share costs and profits equally after payment by
AstraZeneca of a mid-single-digit royalty to Amgen. No payments are
due to Amgen with regard to changes to the agreement.
e)
Brazikumab (inflammatory bowel disease)
In May
2020, AstraZeneca completed a previously communicated agreement to
recover the global rights to brazikumab (formerly MEDI2070), a
monoclonal antibody targeting Interleukin-23. AstraZeneca and
Allergan have terminated their previous licence agreement and all
rights to brazikumab have therefore now returned to the
Company.
COVID-19
a)
AZD1222 (SARS-CoV-2 vaccine)
During
the period, AstraZeneca advanced its ongoing response to address
COVID-19 including licence, development and distribution agreements
with the University of Oxford for the recombinant adenovirus
vaccine, AZD1222.
The
Phase I/II COV001 trial, launched in April 2020 in the UK with more
than 1,000 participants, is ongoing. Initial data was reviewed in
May 2020 by a Data Safety Monitoring Board and the UK Medicines and
Healthcare products Regulatory Agency, resulting in the advancement
to the COV002 Phase II/III trial in the UK, with over 10,000
participants.
In July
2020, results from the COV001 trial were published in The
Lancet, showing that AZD1222 was tolerated and generated
robust immune responses against the SARS-CoV-2 virus in evaluated
participants. Neutralising activity against SARS-CoV-2 (as assessed
by the MNA80 assay) was seen in 91% of participants (32/35) one
month after vaccination and in 100% (10/10) of participants who
received a second dose. In all evaluated participants, a T-cell
response was induced, peaking by day 14, and maintained two months
after injection. The levels of neutralising antibodies seen in
participants receiving either one or two doses were in a similar
range to those seen in convalescent COVID-19 patients. Data from
these assays correlated positively with antibody levels to the
SARS-CoV-2 spike protein, as measured by Enzyme-Linked
Immunosorbent Assays data on the other participants.
COV002
has launched and has recruited almost 9,000 participants in the UK;
late-stage development has begun in Brazil and South Africa. As
part of the announced agreement with
BARDA, the Company anticipates the launch of a Phase III clinical
trial with c.30,000 participants in the US in the third quarter of
this year.
b)
AZD7442 (neutralising-antibody therapy for the prevention and
treatment of COVID-19)
The
Company’s comprehensive pandemic response includes rapid
mobilisation of AstraZeneca’s global research efforts to
discover novel coronavirus-neutralising antibodies to prevent and
treat progression of the COVID-19 disease. During the period,
AstraZeneca announced it had licensed coronavirus-neutralising
antibodies from Vanderbilt University, US, and plans to advance two
of these monoclonal antibodies (AZD8895 and AZD1061) into clinical
development as a potential combination therapy (AZD7442) for the
prevention and treatment of COVID-19. AstraZeneca has secured
support from the Defense Advanced Research Projects Agency, part of
the US Department of Defense and BARDA for the Phase I trial and
the manufacturing of the potential new medicine for testing in
Phase I, which is expected to initiate in the second half of the
year.
In July
2020, the UK Government announced an agreement in principle with
AstraZeneca for the supply of one million doses of AZD7442, with
deliveries anticipated to start as early as first half of 2021,
should the monoclonal-antibody combination prove to be tolerated
and effective in clinical trials.
c)
New and existing medicines in the treatment of
COVID-19
As well
as developing preventative approaches against the SARS-CoV-2 virus
the Company also initiated clinical trials, detailed in the table
below, to investigate AstraZeneca’s new and existing
medicines to treat the infection by suppressing the body’s
overactive immune response or protecting from serious
complications, such as organ failure.
The
Company is continuing to evaluate the use of Calquence, approved in a number of
countries for the treatment of CLL, in the CALAVI Phase II trial,
which is assessing the suppression of the cytokine storm that
inflames the lungs and other organs of some COVID-19 patients.
AstraZeneca is also looking at protecting organs in the Phase II
DARE-19 trial, assessing whether Farxiga can potentially reduce organ
failure. Farxiga is being
evaluated in combination with ambrisentan in the Cambridge
University Hospitals NHS Trust’s TACTIC-E trial. Farxiga is an oral SGLT2 inhibitor that
has demonstrated benefits in heart failure and kidney
disease.
The
Company has joined the UK Government’s ACCORD
proof-of-concept clinical-trial platform, to speed the development
of medicines for patients with COVID-19 and is supplying
Pulmicort and Symbicort to externally sponsored
research programmes including the trials detailed
below.
Table 33: Key trials in COVID-1962
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
|
AZD1222
|
||||
|
Phase
I/II
COV00163
(UK)
|
Protection
against COVID-19 in participants aged 18-55
|
Control
or
AZD1222
n=1,077
|
FPCD
Q2
2020
LPCD
Q2
2020
|
Initial
data read out
|
|
Phase
II/III
COV00269
(UK)
|
Protection
against COVID-19 in participants aged 18-55, 55+ and
paediatric
|
Control
or
AZD1222
n=10,260
|
FPCD
Q2
2020
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
Phase
III
D8110C00001
(US)
|
Protection
against COVID-19 in participants aged 18+
|
Placebo
or AZD1222
n=30,000
|
First
data anticipated
H2
2020
|
Initiating
|
|
Phase
I/IIChAdOx1 nCoV-19 ZA64
(South
Africa)
|
Protection
against COVID-19 in participants aged 18-65
HIV+65
subgroup
|
Placebo
or AZD1222
n=2,200
|
FPCD
Q2
2020
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
Phase
II/III
COV00366
(Brazil)
|
Protection
against COVID-19 in participants aged 18-55
|
Control
or
AZD1222
n>=5,000
|
FPCD
Q2
2020
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
AZD7442
|
||||
|
Phase
I
|
COVID-19
|
Placebo
or AZD7442
|
-
|
Initiating
|
|
Calquence
|
||||
|
Phase
II
CALAVI
(US and
ex-US)
|
COVID-19
|
Current
SoC or SoC+ Calquence
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
Phase
II
ACCORD67
|
COVID-19
|
Current
SoC or current SoC + Calquence
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
Farxiga
|
||||
|
Phase
II
DARE-19
|
COVID-19
|
Current
SoC or current SoC +
Farxiga
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
Phase
II
TACTIC-E68
|
COVID-19
|
Current
SoC or current SoC + Farxiga + ambrisentan
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
MEDI3506
|
||||
|
Phase
II
ACCORD69
|
COVID-19
|
Current
SoC or current SoC + MEDI3506
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
Pulmicort
|
||||
|
Phase
IIIa
TACTIC-COVID70
|
COVID-19
|
Current
SoC or SoC + Pulmicort
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
Phase
IIIa
STOIC71
|
COVID-19
|
Current
SoC or SoC + Pulmicort
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
|
Symbicort
|
||||
|
Phase
IIIa
INHASCO72
|
COVID-19
|
Current
SoC or SoC + Symbicort
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
For
more details on the development pipeline, including anticipated
timelines for regulatory submission/acceptances, please refer to
the latest Clinical Trials
Appendix available on astrazeneca.com.
Interim Financial Statements
Table 34: Condensed consolidated statement of comprehensive income
- H1 2020
|
For the half
year ended 30
June
|
2020
|
2019
|
|
$m
|
$m
|
|
|
Total Revenue
|
12,629
|
11,314
|
|
Product Sales
|
12,359
|
11,183
|
|
Collaboration Revenue
|
270
|
131
|
|
|
|
|
|
Cost of Sales
|
(2,404)
|
(2,192)
|
|
|
|
|
|
Gross Profit
|
10,225
|
9,122
|
|
|
|
|
|
Distribution costs
|
(191)
|
(159)
|
|
Research and development expense
|
(2,777)
|
(2,622)
|
|
Selling, general and administrative costs
|
(5,354)
|
(5,457)
|
|
Other operating income and expense
|
601
|
706
|
|
|
|
|
|
Operating Profit
|
2,504
|
1,590
|
|
Finance income
|
73
|
96
|
|
Finance expense
|
(661)
|
(728)
|
|
Share of after-tax losses in associates and joint
ventures
|
(20)
|
(59)
|
|
|
|
|
|
Profit Before Tax
|
1,896
|
899
|
|
Taxation
|
(408)
|
(229)
|
|
Profit for the period
|
1,488
|
670
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
Remeasurement of the defined benefit pension liability
|
(205)
|
(247)
|
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
1,069
|
(54)
|
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
6
|
(2)
|
|
Tax on items that will not be reclassified to profit or
loss
|
(79)
|
17
|
|
|
791
|
(286)
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
Foreign exchange arising on consolidation
|
(494)
|
(86)
|
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
(17)
|
(186)
|
|
Fair value movements on cash flow hedges
|
(131)
|
(43)
|
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
(1)
|
14
|
|
Fair value movements on derivatives designated in net investment
hedges
|
60
|
(9)
|
|
Costs of hedging
|
4
|
3
|
|
Tax on items that may be reclassified subsequently to profit or
loss
|
29
|
20
|
|
|
(550)
|
(287)
|
|
Other comprehensive income/(loss) for the period, net of
tax
|
241
|
(573)
|
|
Total comprehensive income for the period
|
1,729
|
97
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
Owners of the Parent
|
1,536
|
723
|
|
Non-controlling interests
|
(48)
|
(53)
|
|
|
1,488
|
670
|
|
Total comprehensive income attributable to:
|
|
|
|
Owners of the Parent
|
1,777
|
150
|
|
Non-controlling interests
|
(48)
|
(53)
|
|
|
1,729
|
97
|
|
Basic earnings per $0.25 Ordinary Share
|
$1.17
|
$0.56
|
|
Diluted earnings per $0.25 Ordinary Share
|
$1.17
|
$0.56
|
|
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,289
|
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,290
|
Table 35: Condensed consolidated statement of comprehensive income
- Q2 2020
|
For the quarter ended 30 June
|
Unreviewed732020
|
Unreviewed2019
|
|
$m
|
$m
|
|
|
Total Revenue
|
6,275
|
5,823
|
|
Product Sales
|
6,048
|
5,718
|
|
Collaboration Revenue
|
227
|
105
|
|
Cost of Sales
|
(984)
|
(1,063)
|
|
Gross Profit
|
5,291
|
4,760
|
|
|
|
|
|
Distribution costs
|
(104)
|
(81)
|
|
Research and development expense
|
(1,389)
|
(1,356)
|
|
Selling, general and administrative costs
|
(2,635)
|
(2,943)
|
|
Other operating income and expense
|
121
|
113
|
|
|
|
|
|
Operating Profit
|
1,284
|
493
|
|
Finance income
|
22
|
41
|
|
Finance expense
|
(329)
|
(361)
|
|
Share of after-tax losses in associates and joint
ventures
|
(16)
|
(32)
|
|
|
|
|
|
Profit Before Tax
|
961
|
141
|
|
Taxation
|
(223)
|
(34)
|
|
Profit for the period
|
738
|
107
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
Remeasurement of the defined benefit pension liability
|
(645)
|
(257)
|
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
898
|
(174)
|
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
(15)
|
(1)
|
|
Tax on items that will not be reclassified to profit or
loss
|
(13)
|
60
|
|
|
225
|
(372)
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
Foreign exchange arising on consolidation
|
114
|
(139)
|
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
363
|
(6)
|
|
Fair value movements on cash flow hedges
|
56
|
11
|
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
(46)
|
(33)
|
|
Fair value movements on derivatives designated in net investment
hedges
|
-
|
(12)
|
|
Costs of hedging
|
9
|
9
|
|
Tax on items that may be reclassified subsequently to profit or
loss
|
(44)
|
(3)
|
|
|
452
|
(173)
|
|
Other comprehensive income/(loss) for the period, net of
tax
|
677
|
(545)
|
|
Total comprehensive income/(loss) for the period
|
1,415
|
(438)
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
Owners of the Parent
|
756
|
130
|
|
Non-controlling interests
|
(18)
|
(23)
|
|
|
738
|
107
|
|
Total comprehensive income attributable to:
|
|
|
|
Owners of the Parent
|
1,432
|
(415)
|
|
Non-controlling interests
|
(17)
|
(23)
|
|
|
1,415
|
(438)
|
|
Basic earnings per $0.25 Ordinary Share
|
$0.58
|
$0.09
|
|
Diluted earnings per $0.25 Ordinary Share
|
$0.58
|
$0.10
|
|
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,311
|
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,312
|
Table 36: Condensed consolidated statement of financial
position
|
|
At 30 Jun 2020
|
At 31 Dec 2019
|
At 30 Jun 2019
|
|
$m
|
$m
|
$m
|
|
|
Assets
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property, plant and equipment
|
7,475
|
7,688
|
7,442
|
|
Right-of-use assets
|
634
|
647
|
702
|
|
Goodwill
|
11,645
|
11,668
|
11,668
|
|
Intangible assets
|
19,728
|
20,833
|
22,257
|
|
Investments in associates and joint ventures
|
41
|
58
|
73
|
|
Other investments
|
1,577
|
1,401
|
1,362
|
|
Derivative financial instruments
|
122
|
61
|
124
|
|
Other receivables
|
644
|
740
|
454
|
|
Deferred tax assets
|
3,133
|
2,718
|
2,588
|
|
|
|
|
|
|
|
44,999
|
45,814
|
46,670
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
3,562
|
3,193
|
3,197
|
|
Trade and other receivables
|
5,024
|
5,761
|
5,319
|
|
Other investments
|
442
|
849
|
819
|
|
Derivative financial instruments
|
16
|
36
|
210
|
|
Income tax receivable
|
213
|
285
|
246
|
|
Cash and cash equivalents
|
5,673
|
5,369
|
5,428
|
|
Assets held for sale
|
-
|
70
|
-
|
|
|
14,930
|
15,563
|
15,219
|
|
|
|
|
|
|
Total assets
|
59,929
|
61,377
|
61,889
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Interest-bearing loans and borrowings
|
(3,958)
|
(1,822)
|
(1,629)
|
|
Lease liabilities
|
(174)
|
(188)
|
(206)
|
|
Trade and other payables
|
(12,028)
|
(13,987)
|
(12,637)
|
|
Derivative financial instruments
|
(35)
|
(36)
|
(11)
|
|
Provisions
|
(612)
|
(723)
|
(410)
|
|
Income tax payable
|
(1,376)
|
(1,361)
|
(1,141)
|
|
|
(18,183)
|
(18,117)
|
(16,034)
|
|
Non-current liabilities
|
|
|
|
|
Interest-bearing loans and borrowings
|
(15,150)
|
(15,730)
|
(17,355)
|
|
Lease liabilities
|
(465)
|
(487)
|
(514)
|
|
Derivative financial instruments
|
(121)
|
(18)
|
(2)
|
|
Deferred tax liabilities
|
(2,526)
|
(2,490)
|
(2,932)
|
|
Retirement benefit obligations
|
(2,847)
|
(2,807)
|
(2,632)
|
|
Provisions
|
(835)
|
(841)
|
(376)
|
|
Other payables
|
(6,144)
|
(6,291)
|
(6,973)
|
|
|
(28,088)
|
(28,664)
|
(30,784)
|
|
Total liabilities
|
(46,271)
|
(46,781)
|
(46,818)
|
|
|
|
|
|
|
Net assets
|
13,658
|
14,596
|
15,071
|
|
|
|
|
|
|
Equity
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
|
Share capital
|
328
|
328
|
328
|
|
Share premium account
|
7,950
|
7,941
|
7,911
|
|
Other reserves
|
2,046
|
2,046
|
2,044
|
|
Retained earnings
|
1,913
|
2,812
|
3,265
|
|
|
|
|
|
|
|
12,237
|
13,127
|
13,548
|
|
|
|
|
|
|
Non-controlling interests
|
1,421
|
1,469
|
1,523
|
|
Total equity
|
13,658
|
14,596
|
15,071
|
Table 37: Condensed consolidated statement of changes in
equity
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
At 1 Jan 2019
|
317
|
4,427
|
2,041
|
5,683
|
12,468
|
1,576
|
14,044
|
|
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards
|
-
|
-
|
-
|
54
|
54
|
-
|
54
|
|
Profit for the period
|
-
|
-
|
-
|
723
|
723
|
(53)
|
670
|
|
Other comprehensive loss
|
-
|
-
|
-
|
(573)
|
(573)
|
-
|
(573)
|
|
Transfer to other reserves
|
-
|
-
|
3
|
(3)
|
-
|
-
|
-
|
|
Transactions with owners:
|
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(2,403)
|
(2,403)
|
-
|
(2,403)
|
|
Issue of Ordinary Shares
|
11
|
3,484
|
-
|
-
|
3,495
|
-
|
3,495
|
|
Share-based payments charge for the period
|
-
|
-
|
-
|
102
|
102
|
-
|
102
|
|
Settlement of share plan awards
|
-
|
-
|
-
|
(318)
|
(318)
|
-
|
(318)
|
|
|
|
|
|
|
|
|
|
|
Net movement
|
11
|
3,484
|
3
|
(2,418)
|
1,080
|
(53)
|
1,027
|
|
|
|
|
|
|
|
|
|
|
At 30 Jun 2019
|
328
|
7,911
|
2,044
|
3,265
|
13,548
|
1,523
|
15,071
|
|
|
|
|
|
|
|
|
|
|
At 1 Jan 2020
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
|
|
|
|
|
|
|
|
|
|
Profit for the period
|
-
|
-
|
-
|
1,536
|
1,536
|
(48)
|
1,488
|
|
Other comprehensive income
|
-
|
-
|
-
|
241
|
241
|
-
|
241
|
|
Transfer to other reserves
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Transactions with owners:
|
|
|
|
|
|
|
-
|
|
Dividends
|
-
|
-
|
-
|
(2,489)
|
(2,489)
|
-
|
(2,489)
|
|
Issue of Ordinary Shares
|
-
|
9
|
-
|
-
|
9
|
-
|
9
|
|
Share-based payments charge for the period
|
-
|
-
|
-
|
118
|
118
|
-
|
118
|
|
Settlement of share plan awards
|
-
|
-
|
-
|
(305)
|
(305)
|
-
|
(305)
|
|
|
|
|
|
|
|
|
|
|
Net movement
|
-
|
9
|
-
|
(899)
|
(890)
|
(48)
|
(938)
|
|
|
|
|
|
|
|
|
|
|
At 30 Jun 2020
|
328
|
7,950
|
2,046
|
1,913
|
12,237
|
1,421
|
13,658
|
Table 38: Condensed consolidated statement of cash
flows
|
For the half year ended 30 June
|
2020
|
2019
|
|
$m
|
$m
|
|
|
Cash flows from operating activities
|
|
|
|
Profit Before Tax
|
1,896
|
899
|
|
Finance income and expense
|
588
|
632
|
|
Share of after-tax losses of associates and joint
ventures
|
20
|
59
|
|
Depreciation, amortisation and impairment
|
1,551
|
1,403
|
|
Increase in working capital and short-term provisions
|
(780)
|
(634)
|
|
Gains on disposal of intangible assets
|
(411)
|
(590)
|
|
Fair value movements on contingent consideration arising from
business combinations
|
(44)
|
-
|
|
Non-cash and other movements
|
(511)
|
(177)
|
|
|
|
|
|
Cash generated from operations
|
2,309
|
1,592
|
|
Interest paid
|
(338)
|
(378)
|
|
Tax paid
|
(792)
|
(723)
|
|
|
|
|
|
Net cash inflow from operating activities
|
1,179
|
491
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
Payment of contingent consideration from business
combinations
|
(353)
|
(368)
|
|
Purchase of property, plant and equipment
|
(370)
|
(438)
|
|
Disposal of property, plant and equipment
|
67
|
27
|
|
Purchase of intangible assets
|
(983)
|
(1,296)
|
|
Disposal of intangible assets
|
474
|
1,071
|
|
Movement
in profit-participation liability
|
-
|
150
|
|
Purchase of non-current asset investments
|
(119)
|
(7)
|
|
Disposal of non-current asset investments
|
949
|
18
|
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
463
|
21
|
|
Payments to associates and joint ventures
|
(8)
|
(39)
|
|
Interest received
|
37
|
72
|
|
|
|
|
|
Net cash inflow/(outflow) from investing activities
|
157
|
(789)
|
|
|
|
|
|
Net cash inflow/(outflow) before financing activities
|
1,336
|
(298)
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
Proceeds from issue of share capital
|
9
|
3,495
|
|
Issue of loans
|
-
|
500
|
|
Repayment of loans
|
-
|
(500)
|
|
Dividends paid
|
(2,398)
|
(2,432)
|
|
Hedge contracts relating to dividend payments
|
(93)
|
26
|
|
Repayment of obligations under leases
|
(107)
|
(84)
|
|
Movement in short-term borrowings
|
1,353
|
(64)
|
|
|
|
|
|
Net cash (outflow)/inflow from financing activities
|
(1,236)
|
941
|
|
|
|
|
|
Net increase in cash and cash equivalents in the
period
|
100
|
643
|
|
Cash and cash equivalents at the beginning of the
period
|
5,223
|
4,671
|
|
Exchange rate effects
|
(18)
|
16
|
|
|
|
|
|
Cash and cash equivalents at the end of the period
|
5,305
|
5,330
|
|
|
|
|
|
Cash and cash equivalents consist of:
|
|
|
|
Cash and cash equivalents
|
5,673
|
5,428
|
|
Overdrafts
|
(368)
|
(98)
|
|
|
|
|
|
|
5,305
|
5,330
|
Responsibility statement of the directors in respect of the
half-yearly financial report
We
confirm that to the best of our knowledge:
-
the condensed
consolidated Interim Financial Statements have been prepared in
accordance with IAS 34 ‘Interim Financial Reporting’ as
issued by the International Accounting Standards Board and adopted
by the European Union;
-
the half-yearly
management report includes a fair review of the information
required by:
a)
DTR 4.2.7R of the
Disclosure and Transparency Rules, being an indication of important
events that have occurred during the first six months of the
financial year and their impact on the condensed consolidated
Interim Financial Statements; and a description of the principal
risks and uncertainties for the remaining six months of the year;
and
b)
DTR 4.2.8R of the
Disclosure and Transparency Rules, being related party transactions
that have taken place in the first six months of the current
financial year and that have materially affected the financial
position or performance of the enterprise during that period; and
any changes in the related party transactions described in the last
annual report that could do so.
The Board
The
Board of Directors that served during all or part of the six-month
period to 30 June 2020 and their respective responsibilities can be
found on the Leadership team
section of astrazeneca.com.
Approved
by the Board and signed on its behalf by
Pascal
Soriot
Chief
Executive Officer
30 July 2020
Independent review report to AstraZeneca PLC
Report on the condensed consolidated interim financial
statements
Our conclusion
We have reviewed AstraZeneca PLC's condensed consolidated interim
financial statements (the ‘Interim Financial
Statements’) in the half-yearly financial report of
AstraZeneca PLC for the 6-month period ended 30 June 2020. Based on
our review, nothing has come to our attention that causes us to
believe that the Interim Financial Statements are not prepared, in
all material respects, in accordance with International Accounting
Standard 34, ‘Interim Financial Reporting’, as issued
by the International Accounting Standards Board (IASB) and as
adopted by the European Union and the Disclosure Guidance and
Transparency Rules sourcebook of the United Kingdom’s
Financial Conduct Authority.
What we have reviewed
The Interim Financial Statements comprise:
-
the
Condensed consolidated statement of financial position as at 30
June 2020;
-
the
Condensed consolidated statement of comprehensive income – H1
2020 for the period then ended;
-
the
Condensed consolidated statement of cash flows for the period then
ended;
-
the
Condensed consolidated statement of changes in equity for the
period then ended; and
-
the
explanatory notes to the Interim Financial Statements.
The Interim Financial Statements included in the half-yearly
financial report have been prepared in accordance with
International Accounting Standard 34, ‘Interim Financial
Reporting’, as issued by the IASB and as adopted by the
European Union and the Disclosure Guidance and Transparency Rules
sourcebook of the United Kingdom’s Financial Conduct
Authority.
As disclosed in note 1 to the Interim Financial Statements, the
financial reporting framework that has been applied in the
preparation of the full annual financial statements of the Group is
applicable law and International Financial Reporting
Standards as issued by the IASB and as
adopted by the European Union.
Responsibilities for the interim financial statements and the
review
Our responsibilities and those of the directors
The half-yearly financial report, including the Interim Financial
Statements, is the responsibility of, and has been approved by, the
directors. The directors are responsible for preparing the
half-yearly financial report in accordance with the Disclosure
Guidance and Transparency Rules sourcebook of the United
Kingdom’s Financial Conduct Authority.
Our responsibility is to express a conclusion on the Interim
Financial Statements in the half-yearly financial report based on
our review. This report, including the conclusion, has been
prepared for and only for the company for the purpose of complying
with the Disclosure Guidance and Transparency Rules sourcebook of
the United Kingdom’s Financial Conduct Authority and for no
other purpose. We do not, in giving this conclusion, accept or
assume responsibility for any other purpose or to any other person
to whom this report is shown or into whose hands it may come save
where expressly agreed by our prior consent in
writing.
What a review of interim financial statements involves
We
conducted our review in accordance with International Standard on
Review Engagements (UK and Ireland) 2410, ‘Review of Interim
Financial Information Performed by the Independent Auditor of the
Entity’ issued by the Auditing Practices Board for use in the
United Kingdom. A review of interim financial information consists
of making enquiries, primarily of persons responsible for financial
and accounting matters, and applying analytical and other review
procedures.
A
review is substantially less in scope than an audit conducted in
accordance with International Standards on Auditing (UK) and,
consequently, does not enable us to obtain assurance that we would
become aware of all significant matters that might be identified in
an audit. Accordingly, we do not express an audit
opinion.
We have
read the other information contained in the half-yearly financial
report and considered whether it contains any apparent
misstatements or material inconsistencies with the information in
the Interim Financial Statements.
PricewaterhouseCoopers
LLP
Chartered
Accountants
London
30 July
2020
Notes to the Interim Financial Statements
1)
Basis of preparation and accounting policies
These
unaudited Interim Financial Statements for the six months ended 30
June 2020 have been prepared in accordance with IAS 34
‘Interim Financial Reporting’ as issued by the
International Accounting Standards Board (IASB) and as adopted by
the EU. The UK is in the process of establishing its post-Brexit
IFRS-adoption authority, which is expected to be operational later
in 2020, but for the current time, will follow the EU approval
process.
The
unaudited Interim Financial Statements for the six months ended 30
June 2020 were approved by the Board of Directors for release on 30
July 2020.
The
annual financial statements of the Group are prepared in accordance
with IFRSs as issued by the IASB and adopted by the EU. Except as
noted below, the Interim Financial Statements have been prepared
applying the accounting policies that were applied in the
preparation of the Group’s published consolidated financial
statements for the year ended 31 December 2019.
IFRS 3
An
amendment to IFRS 3 ‘Business Combinations’ relating to
the definition of a business was endorsed by the EU in April 2020
with an effective date of 1 January 2020. The change in definition
of a business within IFRS 3 introduces an optional concentration
test to perform a simplified assessment of whether an acquired set
of activities and assets is or is not a business on a transaction
by transaction basis. This change is expected to provide more
reliable and comparable information about certain transactions as
it provides more consistency in accounting in the pharmaceutical
industry for substantially similar transactions for which, under
the previous definition, may have been accounted in different ways,
despite limited differences in substance. The Group has adopted
this amendment from the effective date.
IFRS 9, IAS 39 and IFRS 7
Amendments
to IFRS 9 ‘Financial Instruments’, IAS 39
‘Financial Instruments: Recognition and Measurement’
and IFRS 7 ‘Financial Instruments: Disclosures’
relating to interbank offered rate (IBOR) reform were endorsed by
the EU in January 2020. The Group adopted the amendments in the
year ended 31 December 2019. The replacement of benchmark interest
rates such as the London Inter-bank Offered Rate (LIBOR) and other
IBORs is a priority for global regulators. The amendments provide
relief from applying specific hedge-accounting requirements to
hedge relationships directly affected by IBOR reform and have the
effect that IBOR reform should generally not cause hedge accounting
to terminate. There is no financial impact from the early adoption
of these amendments.
The
Group has one IFRS 9 designated hedge relationship that is
potentially impacted by IBOR reform, namely a €300m
cross-currency interest-rate swap in a fair-value hedge
relationship with €300m of a €750m 0.875% 2021
non-callable bond. This swap references three-month USD LIBOR and
uncertainty arising from the Group’s exposure to IBOR reform
will cease when the swap matures in 2021. The implications on the
wider business of IBOR reform are currently being
assessed.
COVID-19
AstraZeneca
has assessed the impact of the uncertainty presented by the
COVID-19 pandemic on the Interim Financial Statements comprising
the financial results to 30 June 2020 and the financial position as
at 30 June 2020, specifically considering the impact on key
judgements and significant estimates as detailed on page 173 of the
Annual
Report and 20-F Information 2019 along with a several other
areas of increased risk.
A
detailed assessment has been performed, focussing on the following
areas:
-
recoverable value
of goodwill, intangible assets and property, plant and
equipment
-
impact on key
assumptions used to estimate contingent-consideration
liabilities
-
key assumptions
used in estimating the Group’s defined-benefit pension
obligations
-
basis for
estimating clinical-trial accruals
-
key assumptions
used in estimating rebates, chargebacks and returns for US Product
Sales
-
valuations of
unlisted equity investments
-
expected credit
losses associated with changes in credit risk relating to trade and
other receivables
-
net realisable
value of inventories
-
fair value of
certain financial instruments
-
recoverability of
deferred-tax assets
-
effectiveness of
hedge relationships
Given
the significant volatility experienced in the financial markets,
the assumptions used to estimate the Group’s material
defined-benefit pension obligations are updated quarterly and
resulted in an overall $40m increase in the Group’s
defined-benefit pension deficit in the six months ended 30 June
2020. The increase in the deficit primarily reflected increased
liability valuations as a result of lower discount rates (due to
falling long term AA corporate bond yields linked to the launch of
a quantitative easing bond-buying programme in the UK and other
regions in June 2020), with an increase in asset values providing a
partial offset. In the UK, £79m of deficit-recovery
contributions were also paid during the period. The sensitivity of
the Group’s main defined-benefit liability valuations to
changes in assumptions is set out on page 207 of the Annual Report and Form
20-F Information 2019.
No
further material accounting impacts relating to the areas assessed
above were recognised during the six-month period ending 30 June
2020.
The
Group will continue to monitor these areas of increased judgement,
estimation and risk for material changes.
Going concern
The
Group has considerable financial resources available. As at 30 June
2020, the Group had $10.2bn in financial resources (cash and
cash-equivalent balances of $5.7bn, $0.4bn of liquid fixed income
securities and undrawn committed bank facilities of $4.1bn, of
which $3.4bn is available until April 2022, $0.5bn is available
until November 2020 (extendable to November 2021) and $0.2bn is
available until December 2020, with only $4.1bn of borrowings due
within one year). The Group’s revenues are largely derived
from sales of medicines that are covered by patents which provide a
relatively high level of resilience and predictability to cash
inflows, although government price interventions in response to
budgetary constraints are expected to continue to affect adversely
revenues in many of the mature markets. The Group, however,
anticipates new revenue streams from both recently launched
medicines and those in development, and the Group has a wide
diversity of customers and suppliers across different geographic
areas. Consequently, the Directors believe that, overall, the Group
is well placed to manage its business risks successfully. In the
current environment, the Directors have also considered the impact
of possible future COVID-19 related scenarios and believe the Group
retains sufficient liquidity to continue to operate.
Based
on the above paragraph, the going-concern basis has been adopted in
these Interim Financial Statements.
Legal proceedings
The
information contained in Note 5 updates the disclosures concerning
legal proceedings and contingent liabilities in the Group’s
Annual
Report and Form 20-F Information 2019.
Financial information
The
comparative figures for the financial year ended 31 December 2019
are not the Group’s statutory accounts for that financial
year. Those accounts have been reported on by the Group’s
auditors and have been delivered to the registrar of companies;
their report was (i) unqualified, (ii) did not include a reference
to any matters to which the auditors drew attention by way of
emphasis without qualifying their report, and (iii) did not contain
a statement under section 498(2) or (3) of the Companies Act
2006.
2)
Intangible assets
In
accordance with IAS 36 ‘Impairment of Assets’, reviews
for triggers at an individual asset or cash-generating-unit level
were conducted. This resulted in a total impairment charge of $119m
being recorded against intangible assets during the six months
ended 30 June 2020.
During
the first quarter of 2020, a charge of $102m was recorded in
relation to Bydureon
(revised carrying amount of $612m). The impairment was driven by an
overall reduction in forecast Total Revenue over the remaining
asset life, reflecting expectations of returns from promotional
activities, including a level of anticipated impact resulting from
the restrictions in place due to the COVID-19 pandemic. If Total
Revenue projections for Bydureon were to decline by a further
10% over the forecast period, it would result in a reduction in the
recoverable amount of c.$100m.
During
the second quarter, charges recorded included $65m and $31m in
relation to Duaklir and
Eklira/Tudorza, respectively, (revised
carrying amount of $274m and $130m, respectively), and a $95m
impairment reversal in relation to FluMist (revised carrying amount of
$258m).
The
impairment charges for Duaklir and Eklira/Tudorza were a consequence of revised
market volume and share assumptions following adverse performances
during H1 2020, compared to previous forecasts during the H1 2020.
If Total Revenue projections for these assets were to decline by a
further 20% over the forecast period, it would result in additional
reductions to the recoverable amounts of c.$60m for Duaklir and c.$30m for Eklira/Tudorza.
The
$95m impairment reversal in relation to FluMist reflected a change in expected
sales volumes, following pre-orders received during the
period.
3)
Net Debt
The
table below provides an analysis of Net Debt and a reconciliation
of Net Cash Flow to the movement in Net Debt. The Group monitors
Net Debt as part of its capital-management policy as described in
Note 27 of the Annual Report and Form
20-F Information 2019. Net Debt is a non-GAAP financial
measure.
Table 39: Net Debt
|
|
At
1 Jan 2020
|
Cash flow
|
Non-cash & other
|
Exchange movements
|
At
30 Jun 2020
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
|
Non-current instalments of loans
|
(15,730)
|
-
|
550
|
30
|
(15,150)
|
|
Non-current instalments of leases
|
(487)
|
-
|
11
|
11
|
(465)
|
|
|
|
|
|
|
|
|
Total long-term debt
|
(16,217)
|
-
|
561
|
41
|
(15,615)
|
|
|
|
|
|
|
|
|
Current instalments of loans
|
(1,597)
|
-
|
(556)
|
(6)
|
(2,159)
|
|
Current instalments of leases
|
(188)
|
117
|
(107)
|
4
|
(174)
|
|
Commercial paper
|
-
|
(1,262)
|
-
|
-
|
(1,262)
|
|
Bank collateral
|
(71)
|
(34)
|
-
|
-
|
(105)
|
|
Other short-term borrowings excluding overdrafts
|
(8)
|
(57)
|
-
|
1
|
(64)
|
|
Overdraft
|
(146)
|
(230)
|
-
|
8
|
(368)
|
|
|
|
|
|
|
|
|
Total current debt
|
(2,010)
|
(1,466)
|
(663)
|
7
|
(4,132)
|
|
|
|
|
|
|
|
|
Gross borrowings
|
(18,227)
|
(1,466)
|
(102)
|
48
|
(19,747)
|
|
|
|
|
|
|
|
|
Net derivative financial instruments
|
43
|
93
|
(154)
|
-
|
(18)
|
|
|
|
|
|
|
|
|
Net borrowings
|
(18,184)
|
(1,373)
|
(256)
|
48
|
(19,765)
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
5,369
|
330
|
-
|
(26)
|
5,673
|
|
Other investments - current
|
849
|
(463)
|
62
|
(6)
|
442
|
|
Other investments - non-current
|
62
|
-
|
(62)
|
-
|
-
|
|
Cash and investments
|
6,280
|
(133)
|
-
|
(32)
|
6,115
|
|
|
|
|
|
|
|
|
Net Debt
|
(11,904)
|
(1,506)
|
(256)
|
16
|
(13,650)
|
Non-cash
movements in the period include fair-value adjustments under IFRS
9.
Other
investments - non-current are included within the balance of
$1,577m (31 December 2019: $1,401m) in the Condensed consolidated
statement of financial position. The equivalent GAAP measure to net
debt is ‘liabilities arising from financing activities’
which excludes the amounts for cash and overdrafts, other
investments and non-financing derivatives shown above and includes
the Acerta Pharma put-option liability of $2,219m (31 December
2019: $2,146m) shown in non-current other payables.
Net
Debt increased by $1,746m in the six months to 30 June 2020,
principally due to Net Cash Inflow from Operating Activities of
$1,179m being more than offset by the payment of the second interim
dividend of 2019 of $2,398m (representing two thirds of the 2019
full year).
Details
of the committed undrawn bank facilities are disclosed within the
going-concern section of Note 1.
During
the six months to 30 June 2020, there were no changes to the
Company’s credit ratings issued by Standard and Poor’s
(long term: BBB+, short term A-2) and Moody’s (long term: A3,
short term P-2).
4)
Financial instruments
As
detailed in the Group’s most recent annual financial
statements, the principal financial instruments consist of
derivative financial instruments, other investments, trade and
other receivables, cash and cash equivalents, trade and other
payables, leases and interest-bearing loans and borrowings. During
the period, equity investments previously categorised as Level 3 in
the fair-value hierarchy (carrying value of $103m at 31 December
2019) are now categorised as Level 1 (carrying value of $188m at 30
June 2020) on availability of quoted prices in an active market.
There have been no other changes of significance to the
categorisation or fair-value hierarchy classification of financial
instruments from those detailed in the Notes to the Group Financial
Statements in the Annual Report and Form
20-F Information 2019.
The
Group holds certain equity investments that are categorised as
Level 3 in the fair-value hierarchy and for which fair-value gains
of $65m have been recognised in the six months ended 30 June 2020.
All other fair-value gains and/or losses that are presented in Net
gains/(losses) on Equity Investments measured at fair value through
other comprehensive income in the condensed consolidated statement
of comprehensive income for the six months ended 30 June 2020 are
Level 1 fair value measurements.
Financial
instruments measured at fair value include $2,019m of other
investments, $4,743m held in money-market funds, $339m of loans
designated at fair value through profit or loss, $339m of loans
designated in a fair-value hedge relationship and ($18m) of
derivatives as at 30 June 2020. The total fair value of
interest-bearing loans and borrowings at 30 June 2020, which have a
carrying value of $19,747m in the Condensed consolidated statement
of financial position, was $22,992m. Contingent-consideration
liabilities arising on business combinations have been classified
under Level 3 in the fair-value hierarchy and movements in fair
value are shown below:
Table 40: Financial instruments
|
|
2020
|
2019
|
||
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|
|
$m
|
$m
|
$m
|
$m
|
|
|
At 1 January
|
3,300
|
839
|
4,139
|
5,106
|
|
Settlements
|
(257)
|
(96)
|
(353)
|
(368)
|
|
Revaluations
|
(22)
|
(22)
|
(44)
|
-
|
|
Discount unwind
|
115
|
26
|
141
|
179
|
|
|
|
|
|
|
|
At 30 June
|
3,136
|
747
|
3,883
|
4,917
|
Contingent
consideration arising from business combinations is fair-valued
using decision-tree analysis, with key inputs including the
probability of success, consideration of potential delays and the
expected levels of future revenues.
The
contingent consideration balance relating to BMS’s share of
the global diabetes alliance of $3,136m (31 December 2019: $3,300m)
would increase/decline by $314m with an increase/decline in sales
of 10%, as compared with the current estimates.
Included
within the BMS contingent consideration liability are estimates of
royalties payable in relation to Bydureon. The revised Total Revenue
projections for Bydureon
also resulted in a $22m reduction in the contingent consideration
balance as at 30 June 2020. A further 10% reduction in Bydureon Total Revenue would result in
an additional $22m reduction.
5)
Legal proceedings and contingent liabilities
AstraZeneca
is involved in various legal proceedings considered typical to its
business, including litigation and investigations relating to
product liability, commercial disputes, infringement of
intellectual property rights, the validity of certain patents,
anti-trust law and sales and marketing practices. The matters
discussed below constitute the more significant developments since
publication of the disclosures concerning legal proceedings in the
Company's Annual Report and Form 20-F Information 2019 (the
Disclosures). Unless noted otherwise below or in the Disclosures,
no provisions have been established in respect of the claims
discussed below.
As
discussed in the Disclosures, for the majority of claims in which
AstraZeneca is involved, it is not possible to make a reasonable
estimate of the expected financial effect, if any, that will result
from ultimate resolution of the proceedings. In these cases,
AstraZeneca discloses information with respect only to the nature
and facts of the cases, but no provision is made.
In
cases that have been settled or adjudicated, or where quantifiable
fines and penalties have been assessed and which are not subject to
appeal, or where a loss is probable and we are able to make a
reasonable estimate of the loss, AstraZeneca records the loss
absorbed or makes a provision for its best estimate of the expected
loss. The position could change over time and the estimates that
the Company made, and upon which the Company has relied in
calculating these provisions are inherently imprecise. There can,
therefore, be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed the amount of the
provisions that have been booked in the accounts. The major factors
causing this uncertainty are described more fully in the
Disclosures and herein.
AstraZeneca
has full confidence in, and will vigorously defend and enforce, its
intellectual property.
Matters disclosed in respect of the second quarter of 2020 and to
30 July 2020
Patent litigation
Tagrisso
US patent proceedings
As
previously disclosed, in February 2020, in response to Paragraph IV
notices from multiple abbreviated new drug application (ANDA)
filers, AstraZeneca filed patent infringement lawsuits in the US
District Court for the District of Delaware. In its complaint,
AstraZeneca alleged that a generic version of Tagrisso, if approved and marketed,
would infringe a US Orange Book-listed Tagrisso patent. The trial is scheduled
for May 2022.
Faslodex
Patent proceedings outside the US
In Italy, Actavis Group Ptc ehf and Actavis Italy S.p.A. filed
actions alleging that the Italian part of European Patent No. EP
1,250,138 (the ‘138 patent) and European Patent Nos. EP
2,266,573 (the ‘573 patent) are invalid. In July 2018, the
Court of Turin determined that the ‘138 patent is invalid. In
July 2019, the Court of Milan determined that the ‘573 patent
is invalid. AstraZeneca appealed both decisions. In June 2020, the
Court of Appeal of Turin upheld the invalidity decision as to the
‘138 patent. Patent infringement and patent-invalidity
proceedings are ongoing against various parties.
In
Russia, in July 2020, following a challenge to the validity of the
Faslodex formulation patent
by ZAO BIOCAD (Biocad), the Russian
Patent Office maintained the patent as valid and dismissed
the opposition filed by Biocad.
Symbicort
US patent proceedings
As
previously disclosed, AstraZeneca has ANDA litigation against Mylan
Pharmaceuticals Inc. (Mylan) and 3M Company (3M) in the US District
Court for the Northern District of West Virginia. In the action,
AstraZeneca alleges that the defendants’ generic versions of
Symbicort, if approved and
marketed, would infringe various AstraZeneca patents. Mylan and 3M
allege that their proposed generic product does not infringe the
asserted patents and/or that the asserted patents are invalid
and/or unenforceable. In July 2020, AstraZeneca added Kindeva Drug
Delivery L.P. as a defendant in the case. The trial of the matter
is scheduled for October 2020.
Product liability litigation
Nexium and Losec/Prilosec
As
previously disclosed, in the US, AstraZeneca is defending various
lawsuits brought in federal and state courts involving multiple
plaintiffs claiming that they have been diagnosed with various
injuries following treatment with proton pump inhibitors (PPIs),
including Nexium and
Prilosec. The vast majority
of those lawsuits relate to allegations of kidney injuries. In
particular, in May 2017, counsel for a group of such plaintiffs
claiming that they have been diagnosed with kidney injuries filed a
motion with the Judicial Panel on Multidistrict Litigation (JPML)
seeking the transfer of any currently pending federal court cases
as well as any similar, subsequently filed cases to a coordinated
and consolidated pre-trial multidistrict litigation (MDL)
proceeding. In August 2017, the JPML granted the motion and
consolidated the pending federal court cases in an MDL proceeding
in federal court in New Jersey for pre-trial purposes. A trial in
the MDL has been scheduled for November 2021. In addition to the
MDL cases, there are cases filed in several state courts around the
US.
In
addition, AstraZeneca has been defending lawsuits involving
allegations of gastric cancer following treatment with PPIs. All
but one of these claims is filed in the MDL. One claim is filed in
the US District Court for the Middle District of Louisiana, where
the court has scheduled a trial for March 2022.
Commercial litigation
Amplimmune
As
previously disclosed, in June 2017, AstraZeneca was served with a
lawsuit filed by the stockholders' agents for Amplimmune, Inc.
(Amplimmune) in Delaware State Court that alleged, among other
things, breaches of contractual obligations relating to a 2013
merger agreement between AstraZeneca and Amplimmune. Trial of the
matter was held in February 2020 and post-trial oral argument is
scheduled for August 2020.
Array
In
December 2017, AstraZeneca was served with a complaint
filed in New York State court by Array BioPharma, Inc. (Array)
alleging breaches of contractual
obligations relating to a 2003 collaboration agreement between
AstraZeneca and Array. In June 2020, an appeal court denied
AstraZeneca’s motion for an early dismissal of the case,
allowing the case to continue towards trial. No trial date has been
set.
Anti-Terrorism Act Civil Lawsuit
As
previously disclosed, in October 2017, AstraZeneca and certain
other pharmaceutical and/or medical device companies were named as
defendants in a complaint, filed in the US District Court for the
District of Columbia (the District Court) by US nationals (or their
estates, survivors, or heirs) who were killed or wounded in Iraq
between 2005 and 2011, that alleged that the defendants violated
the US Anti-Terrorism Act and various state laws by selling
pharmaceuticals and medical supplies to the Iraqi Ministry of
Health. In July 2020, the District Court granted
AstraZeneca’s and its co-defendants’ jointly filed
motion and dismissed the lawsuit in its entirety.
Ocimum lawsuit
In
December 2017, AstraZeneca was served with a complaint filed by
Ocimum Biosciences, Ltd. (Ocimum) in the Superior Court for the
State of Delaware that alleges, among other things, breaches of
contractual obligations and misappropriation of trade secrets,
relating to a now terminated 2001 licensing agreement between
AstraZeneca and Gene Logic, Inc. (Gene Logic), the rights to which
Ocimum purports to have acquired from Gene Logic. In December 2019,
the court granted AstraZeneca’s motion for summary judgment
and dismissed the case. Ocimum has appealed.
Government investigations/proceedings
Synagis
Litigation in New York
As
previously disclosed, in the US, in June 2011, MedImmune received a
demand from the US Attorney’s Office for the Southern
District of New York requesting certain documents related to the
sales and marketing activities of Synagis. In July 2011, MedImmune
received a similar court order to produce documents from the Office
of the Attorney General for the State of New York Medicaid and
Fraud Control Unit pursuant to what the government attorneys
advised was a joint investigation. MedImmune has cooperated with
these inquiries.
In
March 2017, MedImmune was served with a lawsuit filed in US
District Court for the Southern District of New York by the
Attorney General for the State of New York alleging that MedImmune
inappropriately provided assistance to a single specialty care
pharmacy. In September 2018, the US District Court in New York
denied MedImmune’s motion to dismiss the lawsuit brought by
the Attorney General for the State of New York. This matter has
been resolved and is now concluded.
In June
2017, MedImmune was served with a lawsuit in US District Court for
the Southern District of New York by a relator under the qui tam
(whistleblower) provisions of the federal and certain state False
Claims Acts. The lawsuit was originally filed under seal in April
2009 and alleges that MedImmune made false claims about
Synagis. In November 2017,
MedImmune was served with an amended complaint in which relator set
forth additional false claims allegations relating to Synagis. In
September 2018, the US District Court in New York dismissed the
relator’s lawsuit. In January 2019, relator appealed the
decision of the US District Court in New York. In March 2020, the
United States Court of Appeals for the Second Circuit affirmed the
US District Court’s decision dismissing the relator’s
lawsuit. This matter is now concluded.
Toprol-XL
Louisiana Attorney General Litigation
As
previously disclosed, in April 2019, a Louisiana state court (State
Court) granted AstraZeneca’s motion for summary judgment and
dismissed a state court complaint brought by the Attorney General
for the State of Louisiana (the State), which alleged that, in
connection with enforcement of its patents for Toprol-XL, AstraZeneca engaged in
unlawful monopolisation and unfair trade practices, causing the
State government to pay increased prices for Toprol-XL, and the State appealed that
ruling. In July 2020, the Louisiana First Court of Appeals reversed
the State Court’s ruling and remanded the case to the State
Court.
Matters disclosed in respect of the first quarter of 2020 and to 29
April 2020
Patent litigation
Tagrisso
US patent proceedings
As
disclosed in February 2020, in response to Paragraph IV notices
from multiple ANDA filers, AstraZeneca filed patent-infringement
lawsuits in the US District Court for the District of Delaware. In
its complaint, AstraZeneca alleged that a generic version of
Tagrisso, if approved and
marketed, would infringe a US Orange Book-listed Tagrisso patent. No trial date has been
set.
Symbicort
US patent proceedings
As
previously disclosed, AstraZeneca has ANDA litigation against Mylan
Pharmaceuticals Inc. (Mylan) and 3M Company (3M) in the US District
Court for the Northern District of West Virginia. In the action,
AstraZeneca alleges that the defendants’ generic versions of
Symbicort, if approved and
marketed, would infringe various AstraZeneca patents. Mylan and 3M
allege that their proposed generic medicines do not infringe the
asserted patents and/or that the asserted patents are invalid
and/or unenforceable. The trial of the Mylan and 3M matter is
scheduled for October 2020.
Movantik
US patent proceedings
In
March 2020, Aether Therapeutics, Inc. filed a patent infringement
lawsuit in the US District Court for the District of Delaware
against AstraZeneca, Nektar Therapeutics and Daiichi Sankyo
relating to Movantik.
Commercial litigation
Amplimmune
As
disclosed in the US in June 2017, AstraZeneca was served with a
lawsuit filed by the stockholders' agents for Amplimmune, Inc.
(Amplimmune) in Delaware State Court that alleged, among other
things, breaches of contractual obligations relating to a 2013
merger agreement between AstraZeneca and Amplimmune. Trial of the
matter was held in February 2020 and post-trial oral argument is
scheduled for June 2020.
Government investigations/proceedings
Crestor
Qui tam litigation
As
previously disclosed, in the US, in January and February 2014,
AstraZeneca was served with lawsuits filed in the US District Court
for the District of Delaware under the qui tam provisions of the
federal False Claims Act and related state statutes, alleging that
AstraZeneca directed certain employees to promote Crestor off-label and provided unlawful
remuneration to physicians in connection with the promotion of
Crestor. The Department of
Justice and all US states declined to intervene in the lawsuits. In
March 2019, AstraZeneca filed a motion to dismiss the complaint. In
February 2020, the District Court partially granted
AstraZeneca’s motion to dismiss.
Synagis
Litigation in New York
As
disclosed in the US in June 2011, MedImmune received a demand from
the US Attorney’s Office for the Southern District of New
York requesting certain documents related to the sales and
marketing activities of Synagis. In July 2011, MedImmune received a
similar court order to produce documents from the Office of the
Attorney General for the State of New York Medicaid and Fraud
Control Unit pursuant to what the government attorneys advised was
a joint investigation. MedImmune has co-operated with these
inquiries. In March 2017, MedImmune was served with a lawsuit filed
in US District Court for the Southern District of New York by the
Attorney General for the State of New York, alleging that MedImmune
inappropriately provided assistance to a single specialty-care
pharmacy. In September 2018, the US District Court in New York
denied MedImmune’s motion to dismiss the lawsuit brought by
the Attorney General for the State of New York.
In June
2017, MedImmune was served with a lawsuit in US District Court for
the Southern District of New York by a relator under the qui tam
(whistle-blower) provisions of the federal and certain state False
Claims Acts. The lawsuit was originally filed under seal in April
2009 and alleged that MedImmune made false claims about Synagis. In
November 2017, MedImmune was served with an amended complaint in
which relator set forth additional false claims’ allegations
relating to Synagis. In
September 2018, the US District Court in New York dismissed the
relator’s lawsuit. In January 2019, relator appealed the
decision of the US District Court in New York. In March 2020, the
United States Court of Appeals for the Second Circuit affirmed the
US District Court’s decision dismissing the relator’s
lawsuit.
Vermont US Attorney investigation
In
April 2020, AstraZeneca received a Civil Investigative Demand from
the US Attorney’s Office in Vermont and the Department of
Justice, Civil Division, seeking documents and information relating
to AstraZeneca’s relationships with electronic health-record
vendors. AstraZeneca intends to co-operate with this
enquiry.
Taxation
As
previously disclosed in the Annual Report and Form
20-F Information 2019, AstraZeneca faces a number of audits
and reviews in jurisdictions around the world and, in some cases,
is in dispute with the tax authorities. The issues under discussion
are often complex and can require many years to resolve. Accruals
for tax contingencies require management to make key judgements
with respect to the ultimate outcome of current and potential
future tax audits, and actual results could vary from these
estimates. The total net accrual to cover the worldwide tax
exposure for transfer pricing and other international tax
contingencies of $139m (December 2019: $140m) reflected the
progress in those tax audits and reviews during the half and for
those audits where AstraZeneca and tax authorities are in dispute,
AstraZeneca estimates the potential for reasonably possible
additional liabilities above and beyond the amount provided to be
up to $226m, including associated interest (December 2019: $76m).
However, the Company believes that it is unlikely that these
additional liabilities will arise. It is possible that some of
these contingencies may reduce in the future to the extent that any
tax authority challenge is concluded, or matters lapse following
expiry of the relevant statutes of limitation resulting in a
reduction in the tax charge in future periods.
There was no material change in the period to the other tax
contingencies.
6)
Subsequent Events
In July
2020, the Company announced that it had entered into a new global
development and commercialisation agreement with Daiichi Sankyo for
DS-1062, its proprietary TROP2-directed antibody drug conjugate and
potential new medicine for the treatment of multiple tumour types.
AstraZeneca will pay Daiichi Sankyo an upfront payment of $1bn in
staged payments, additional conditional amounts of up to $1bn for
the successful achievement of regulatory approvals and up to $4bn
for sales-related milestones. The transaction will be accounted for
as an intangible-asset acquisition, recognised initially at the
present value of non-contingent consideration, with any potential
future milestone payments capitalised into the intangible asset as
they are recognised.
The
companies will jointly develop and commercialise DS-1062 jointly
worldwide, except in Japan where Daiichi Sankyo will maintain
exclusive rights. AstraZeneca and Daiichi Sankyo will share equally
development and commercialisation expenses as well as profits
relating to DS-1062 worldwide, except for Japan where Daiichi
Sankyo will be responsible for such costs and will pay AstraZeneca
mid single-digit royalties. Daiichi Sankyo will record sales in the
US, certain countries in Europe and certain other countries where
Daiichi Sankyo has affiliates. Profits shared with AstraZeneca from
those countries will be recorded as Collaboration Revenue by
AstraZeneca. AstraZeneca will record Product Sales in other
countries worldwide, for which profits shared with Daiichi Sankyo
will be recorded within Cost of Sales. Daiichi Sankyo will
manufacture and supply DS-1062.
7)
Table
41: Product Sales year-on-year analysis - H1 202074
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
2,016
|
43
|
45
|
595
|
81
|
89
|
725
|
30
|
325
|
53
|
58
|
371
|
18
|
18
|
|
Imfinzi
|
954
|
51
|
52
|
63
|
n/m
|
n/m
|
574
|
21
|
167
|
n/m
|
n/m
|
150
|
70
|
71
|
|
Lynparza
|
816
|
57
|
60
|
120
|
n/m
|
n/m
|
406
|
55
|
198
|
51
|
56
|
92
|
35
|
34
|
|
Calquence
|
195
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
193
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Koselugo
|
7
|
n/m
|
n/m
|
-
|
-
|
-
|
7
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Zoladex*
|
442
|
13
|
18
|
288
|
22
|
29
|
5
|
40
|
68
|
5
|
8
|
81
|
(7)
|
(6)
|
|
Faslodex*
|
312
|
(40)
|
(38)
|
100
|
4
|
10
|
34
|
(87)
|
116
|
6
|
9
|
62
|
(4)
|
(4)
|
|
Iressa*
|
147
|
(42)
|
(40)
|
120
|
(27)
|
(24)
|
7
|
(3)
|
9
|
(81)
|
(81)
|
11
|
(67)
|
(66)
|
|
Arimidex*
|
107
|
(3)
|
-
|
90
|
26
|
30
|
-
|
-
|
1
|
(90)
|
(90)
|
16
|
(32)
|
(32)
|
|
Casodex*
|
89
|
(15)
|
(13)
|
69
|
8
|
11
|
-
|
-
|
1
|
(84)
|
(84)
|
19
|
(43)
|
(42)
|
|
Others
|
26
|
(50)
|
(47)
|
14
|
(23)
|
(14)
|
-
|
-
|
3
|
(15)
|
(16)
|
9
|
(64)
|
(69)
|
|
Total Oncology
|
5,111
|
26
|
28
|
1,461
|
39
|
46
|
1,951
|
20
|
888
|
37
|
41
|
811
|
10
|
9
|
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
848
|
17
|
21
|
306
|
49
|
59
|
237
|
(12)
|
223
|
25
|
29
|
82
|
14
|
15
|
|
Brilinta
|
845
|
15
|
17
|
291
|
34
|
40
|
351
|
9
|
173
|
2
|
5
|
30
|
7
|
10
|
|
Onglyza
|
256
|
(5)
|
(3)
|
100
|
15
|
21
|
105
|
(12)
|
29
|
(21)
|
(18)
|
22
|
(15)
|
(13)
|
|
Bydureon
|
216
|
(24)
|
(23)
|
2
|
(74)
|
(72)
|
185
|
(21)
|
24
|
(29)
|
(26)
|
5
|
(37)
|
(34)
|
|
Byetta
|
35
|
(36)
|
(35)
|
5
|
13
|
21
|
19
|
(47)
|
7
|
(29)
|
(26)
|
4
|
(21)
|
(20)
|
|
Other diabetes
|
23
|
3
|
6
|
3
|
n/m
|
n/m
|
13
|
(21)
|
6
|
44
|
50
|
1
|
(60)
|
(25)
|
|
Lokelma
|
28
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
22
|
n/m
|
2
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
Crestor*
|
582
|
(10)
|
(8)
|
369
|
(9)
|
(6)
|
45
|
(17)
|
64
|
(15)
|
(13)
|
104
|
(5)
|
(5)
|
|
Seloken/Toprol-XL*
|
395
|
-
|
6
|
376
|
8
|
14
|
6
|
(78)
|
8
|
(39)
|
(39)
|
5
|
-
|
5
|
|
Atacand*
|
126
|
19
|
25
|
94
|
23
|
31
|
5
|
(15)
|
15
|
(2)
|
(2)
|
12
|
37
|
43
|
|
Others
|
106
|
(20)
|
(18)
|
65
|
(30)
|
(28)
|
-
|
-
|
35
|
15
|
18
|
6
|
(36)
|
(39)
|
|
BioPharmaceuticals: total CVRM
|
3,460
|
3
|
6
|
1,612
|
11
|
17
|
988
|
(9)
|
586
|
3
|
6
|
274
|
-
|
2
|
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
1,442
|
23
|
26
|
290
|
10
|
16
|
558
|
46
|
356
|
1
|
4
|
238
|
39
|
42
|
|
Pulmicort
|
477
|
(33)
|
(32)
|
371
|
(36)
|
(34)
|
36
|
(36)
|
40
|
(8)
|
(4)
|
30
|
(26)
|
(25)
|
|
Fasenra
|
426
|
44
|
45
|
7
|
n/m
|
n/m
|
272
|
31
|
88
|
96
|
n/m
|
59
|
41
|
41
|
|
Daliresp/Daxas
|
106
|
1
|
2
|
2
|
(13)
|
(7)
|
90
|
1
|
13
|
7
|
11
|
1
|
(3)
|
(36)
|
|
Bevespi
|
22
|
10
|
10
|
-
|
-
|
-
|
21
|
5
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Breztri
|
11
|
n/m
|
n/m
|
9
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
|
Others
|
184
|
(20)
|
(18)
|
80
|
(29)
|
(27)
|
7
|
n/m
|
89
|
(16)
|
(14)
|
8
|
(14)
|
4
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
2,668
|
5
|
7
|
759
|
(21)
|
(18)
|
984
|
30
|
587
|
5
|
8
|
338
|
29
|
31
|
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
714
|
(5)
|
(3)
|
371
|
-
|
5
|
80
|
(32)
|
36
|
14
|
18
|
227
|
(4)
|
(4)
|
|
Synagis
|
176
|
18
|
18
|
5
|
n/m
|
n/m
|
21
|
(40)
|
150
|
32
|
32
|
-
|
-
|
-
|
|
Losec/Prilosec
|
99
|
(32)
|
(30)
|
81
|
(15)
|
(12)
|
3
|
(44)
|
10
|
(68)
|
(68)
|
5
|
(62)
|
(62)
|
|
Seroquel XR/IR
|
63
|
(9)
|
(8)
|
27
|
11
|
15
|
14
|
n/m
|
15
|
(69)
|
(69)
|
7
|
(36)
|
(37)
|
|
Others
|
68
|
(32)
|
(31)
|
3
|
(64)
|
(73)
|
33
|
(44)
|
28
|
5
|
5
|
4
|
(34)
|
(22)
|
|
Total other medicines
|
1,120
|
(8)
|
(6)
|
487
|
(2)
|
1
|
151
|
(26)
|
239
|
(4)
|
(4)
|
243
|
(9)
|
(9)
|
|
Total Product Sales
|
12,359
|
11
|
13
|
4,319
|
9
|
14
|
4,074
|
11
|
2,300
|
13
|
17
|
1,666
|
8
|
9
|
8)
Table
42: Product Sales year-on-year analysis - Q2 2020
(Unreviewed)75
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
1,034
|
32
|
35
|
315
|
65
|
74
|
354
|
18
|
163
|
46
|
51
|
202
|
12
|
12
|
|
Imfinzi
|
492
|
46
|
48
|
30
|
n/m
|
n/m
|
287
|
19
|
93
|
n/m
|
n/m
|
82
|
55
|
56
|
|
Lynparza
|
419
|
48
|
52
|
64
|
95
|
n/m
|
209
|
47
|
96
|
45
|
50
|
50
|
20
|
21
|
|
Calquence
|
107
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
107
|
n/m
|
-
|
-
|
-
|
(1)
|
n/m
|
n/m
|
|
Koselugo
|
7
|
n/m
|
n/m
|
-
|
-
|
-
|
7
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Zoladex*
|
217
|
10
|
17
|
139
|
15
|
24
|
3
|
55
|
33
|
8
|
14
|
42
|
(4)
|
(2)
|
|
Faslodex*
|
146
|
(45)
|
(43)
|
52
|
2
|
10
|
11
|
(91)
|
52
|
(7)
|
(3)
|
31
|
(13)
|
(13)
|
|
Iressa*
|
70
|
(41)
|
(38)
|
58
|
(26)
|
(23)
|
4
|
(5)
|
3
|
(85)
|
(85)
|
5
|
(65)
|
(62)
|
|
Arimidex*
|
58
|
(4)
|
-
|
48
|
35
|
41
|
-
|
-
|
1
|
(93)
|
(93)
|
9
|
(42)
|
(43)
|
|
Casodex*
|
47
|
(17)
|
(15)
|
37
|
8
|
11
|
-
|
-
|
-
|
n/m
|
n/m
|
10
|
(47)
|
(46)
|
|
Others
|
12
|
(59)
|
(55)
|
6
|
(35)
|
(18)
|
(1)
|
n/m
|
1
|
(32)
|
(35)
|
6
|
(67)
|
(74)
|
|
Total Oncology
|
2,609
|
20
|
24
|
750
|
34
|
43
|
981
|
15
|
442
|
32
|
37
|
436
|
3
|
4
|
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
443
|
17
|
23
|
165
|
49
|
62
|
124
|
(11)
|
107
|
20
|
25
|
47
|
24
|
26
|
|
Brilinta
|
437
|
12
|
16
|
156
|
30
|
39
|
187
|
11
|
80
|
(9)
|
(5)
|
14
|
6
|
10
|
|
Bydureon
|
116
|
(18)
|
(17)
|
1
|
(87)
|
(86)
|
101
|
(14)
|
12
|
(22)
|
(19)
|
2
|
(23)
|
(18)
|
|
Onglyza
|
115
|
(1)
|
3
|
52
|
19
|
27
|
38
|
(9)
|
14
|
(22)
|
(19)
|
11
|
(20)
|
(17)
|
|
Byetta
|
15
|
(42)
|
(41)
|
2
|
(37)
|
(30)
|
7
|
(53)
|
4
|
(16)
|
(13)
|
2
|
(26)
|
(26)
|
|
Other diabetes
|
10
|
(9)
|
(5)
|
1
|
n/m
|
n/m
|
6
|
(31)
|
3
|
37
|
44
|
-
|
n/m
|
n/m
|
|
Lokelma
|
17
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
12
|
n/m
|
1
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
Crestor*
|
281
|
(10)
|
(6)
|
177
|
(3)
|
2
|
17
|
(40)
|
30
|
(18)
|
(16)
|
57
|
(11)
|
(10)
|
|
Seloken/Toprol-XL*
|
218
|
29
|
38
|
210
|
35
|
45
|
2
|
(53)
|
4
|
(48)
|
(48)
|
2
|
2
|
9
|
|
Atacand*
|
59
|
6
|
14
|
45
|
21
|
33
|
2
|
(39)
|
6
|
(43)
|
(43)
|
6
|
43
|
52
|
|
Others
|
48
|
(23)
|
(20)
|
29
|
(31)
|
(28)
|
-
|
-
|
16
|
25
|
29
|
3
|
(65)
|
(69)
|
|
BioPharmaceuticals: total CVRM
|
1,759
|
6
|
10
|
839
|
20
|
28
|
496
|
(6)
|
277
|
(3)
|
1
|
147
|
(1)
|
1
|
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
653
|
12
|
15
|
135
|
3
|
12
|
248
|
20
|
161
|
(6)
|
(3)
|
109
|
42
|
47
|
|
Pulmicort
|
97
|
(71)
|
(69)
|
58
|
(78)
|
(76)
|
13
|
(60)
|
15
|
(21)
|
(18)
|
11
|
(43)
|
(42)
|
|
Fasenra
|
227
|
36
|
37
|
1
|
(30)
|
(5)
|
152
|
33
|
42
|
57
|
63
|
32
|
32
|
33
|
|
Daliresp/Daxas
|
53
|
(7)
|
(7)
|
1
|
(17)
|
(9)
|
45
|
(7)
|
6
|
(3)
|
1
|
1
|
(37)
|
(70)
|
|
Bevespi
|
10
|
(1)
|
(3)
|
-
|
-
|
-
|
9
|
(6)
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Breztri
|
7
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
|
Others
|
70
|
(30)
|
(28)
|
21
|
(52)
|
(52)
|
5
|
n/m
|
42
|
(18)
|
(15)
|
2
|
(60)
|
(36)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,117
|
(11)
|
(8)
|
221
|
(50)
|
(46)
|
472
|
15
|
267
|
(3)
|
1
|
157
|
23
|
26
|
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
377
|
(4)
|
(1)
|
184
|
3
|
9
|
40
|
(24)
|
15
|
(7)
|
(4)
|
138
|
(5)
|
(5)
|
|
Synagis
|
90
|
(5)
|
(5)
|
-
|
-
|
-
|
14
|
41
|
76
|
(11)
|
(11)
|
-
|
-
|
-
|
|
Losec/Prilosec
|
45
|
(34)
|
(31)
|
37
|
(16)
|
(12)
|
1
|
(90)
|
5
|
(60)
|
(60)
|
2
|
(75)
|
(74)
|
|
Seroquel XR/IR
|
27
|
(16)
|
(14)
|
15
|
49
|
57
|
1
|
n/m
|
7
|
(71)
|
(71)
|
4
|
(23)
|
(25)
|
|
Others
|
24
|
(53)
|
(52)
|
2
|
(88)
|
(93)
|
8
|
(74)
|
13
|
3
|
1
|
1
|
n/m
|
n/m
|
|
Total other medicines
|
563
|
(12)
|
(10)
|
238
|
(5)
|
-
|
64
|
(29)
|
116
|
(23)
|
(23)
|
145
|
(3)
|
(3)
|
|
Total Product Sales
|
6,048
|
6
|
9
|
2,048
|
5
|
12
|
2,013
|
7
|
1,102
|
5
|
9
|
885
|
4
|
5
|
9)
Table 43: Product
Sales quarterly sequential analysis - Q2 2020
(Unreviewed)76
|
|
Q1 2020
|
Q2 2020
|
||||
|
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
|||
|
Oncology
|
|
|
|
|
|
|
|
Tagrisso
|
982
|
11
|
11
|
1,034
|
5
|
7
|
|
Imfinzi
|
462
|
9
|
9
|
492
|
6
|
8
|
|
Lynparza
|
397
|
13
|
13
|
419
|
5
|
7
|
|
Calquence
|
88
|
58
|
58
|
107
|
21
|
23
|
|
Koselugo
|
-
|
-
|
-
|
7
|
n/m
|
n/m
|
|
Zoladex*
|
225
|
15
|
15
|
217
|
(3)
|
-
|
|
Faslodex*
|
166
|
-
|
-
|
146
|
(12)
|
(9)
|
|
Iressa*
|
77
|
(3)
|
(4)
|
70
|
(9)
|
(7)
|
|
Arimidex*
|
50
|
(1)
|
(2)
|
58
|
17
|
16
|
|
Casodex*
|
42
|
(2)
|
(3)
|
47
|
14
|
12
|
|
Others
|
13
|
(52)
|
(52)
|
12
|
(11)
|
(1)
|
|
Total Oncology
|
2,502
|
10
|
10
|
2,609
|
4
|
6
|
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
Farxiga
|
405
|
(3)
|
(3)
|
443
|
9
|
13
|
|
Brilinta
|
408
|
(5)
|
(5)
|
437
|
7
|
9
|
|
Onglyza
|
141
|
8
|
8
|
115
|
(19)
|
(17)
|
|
Bydureon
|
100
|
(28)
|
(28)
|
116
|
16
|
17
|
|
Byetta
|
20
|
(24)
|
(24)
|
15
|
(28)
|
(28)
|
|
Other diabetes
|
13
|
(22)
|
(22)
|
10
|
(21)
|
(19)
|
|
Lokelma
|
11
|
42
|
42
|
17
|
56
|
58
|
|
Crestor*
|
301
|
2
|
1
|
281
|
(7)
|
(4)
|
|
Seloken/Toprol-XL*
|
177
|
(6)
|
(6)
|
218
|
23
|
27
|
|
Atacand*
|
66
|
11
|
12
|
59
|
(11)
|
(5)
|
|
Others
|
59
|
(21)
|
(22)
|
48
|
(18)
|
(16)
|
|
BioPharmaceuticals: total CVRM
|
1,701
|
(5)
|
(5)
|
1,759
|
3
|
6
|
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
Symbicort
|
790
|
11
|
11
|
653
|
(17)
|
(15)
|
|
Pulmicort
|
380
|
(8)
|
(9)
|
97
|
(74)
|
(73)
|
|
Fasenra
|
199
|
(3)
|
(3)
|
227
|
14
|
15
|
|
Daliresp/Daxas
|
53
|
(8)
|
(8)
|
53
|
(1)
|
(3)
|
|
Bevespi
|
12
|
9
|
9
|
10
|
(19)
|
(21)
|
|
Breztri
|
4
|
n/m
|
n/m
|
7
|
58
|
64
|
|
Others
|
113
|
(16)
|
(17)
|
70
|
(38)
|
(36)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,551
|
1
|
1
|
1,117
|
(28)
|
(26)
|
|
Other medicines
|
|
|
|
|
|
|
|
Nexium
|
338
|
(4)
|
(4)
|
377
|
12
|
14
|
|
Synagis
|
85
|
35
|
35
|
90
|
6
|
7
|
|
Losec/Prilosec
|
54
|
18
|
17
|
45
|
(15)
|
(15)
|
|
Seroquel XR/IR
|
36
|
(12)
|
(12)
|
27
|
(26)
|
(23)
|
|
Others
|
44
|
(71)
|
(70)
|
24
|
(46)
|
(42)
|
|
Total other medicines
|
557
|
(15)
|
(15)
|
563
|
1
|
4
|
|
Total Product Sales
|
6,311
|
1
|
1
|
6,048
|
(4)
|
(2)
|
10)
T able 44: Product
Sales quarterly sequential analysis - FY 2019 (Unreviewed)
|
|
Q1 2019
|
Q2 2019
|
Q3 2019
|
Q4 2019
|
||||||||
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
|||||
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
630
|
6
|
6
|
784
|
24
|
25
|
891
|
14
|
13
|
884
|
(1)
|
-
|
|
Imfinzi
|
295
|
13
|
13
|
338
|
15
|
15
|
412
|
22
|
22
|
424
|
3
|
4
|
|
Lynparza
|
237
|
13
|
13
|
283
|
19
|
20
|
327
|
16
|
15
|
351
|
7
|
8
|
|
Calquence
|
29
|
21
|
23
|
35
|
21
|
19
|
44
|
27
|
27
|
56
|
25
|
25
|
|
Faslodex*
|
254
|
(6)
|
(6)
|
267
|
5
|
6
|
205
|
(23)
|
(23)
|
166
|
(20)
|
(19)
|
|
Zoladex*
|
194
|
7
|
6
|
197
|
2
|
1
|
226
|
15
|
16
|
196
|
(14)
|
(12)
|
|
Iressa*
|
134
|
20
|
18
|
118
|
(12)
|
(11)
|
91
|
(23)
|
(22)
|
80
|
(13)
|
(12)
|
|
Arimidex*
|
51
|
11
|
10
|
60
|
18
|
17
|
63
|
5
|
5
|
51
|
(20)
|
(18)
|
|
Casodex*
|
48
|
4
|
3
|
57
|
19
|
18
|
52
|
(8)
|
(6)
|
43
|
(18)
|
(17)
|
|
Others
|
20
|
(13)
|
(14)
|
28
|
40
|
29
|
20
|
(27)
|
(22)
|
26
|
30
|
26
|
|
Total Oncology
|
1,892
|
7
|
6
|
2,167
|
15
|
15
|
2,334
|
8
|
8
|
2,274
|
(3)
|
(2)
|
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
349
|
(12)
|
(12)
|
377
|
8
|
9
|
398
|
5
|
5
|
419
|
5
|
6
|
|
Brilinta
|
348
|
(7)
|
(8)
|
389
|
12
|
12
|
416
|
7
|
8
|
428
|
3
|
3
|
|
Onglyza
|
153
|
3
|
3
|
116
|
(24)
|
(24)
|
127
|
9
|
11
|
131
|
3
|
4
|
|
Bydureon
|
142
|
3
|
3
|
141
|
(1)
|
-
|
127
|
(10)
|
(10)
|
139
|
9
|
10
|
|
Byetta
|
30
|
(6)
|
(5)
|
25
|
(17)
|
(16)
|
28
|
10
|
13
|
27
|
(2)
|
(4)
|
|
Other diabetes
|
11
|
(8)
|
(17)
|
11
|
-
|
8
|
14
|
26
|
22
|
16
|
17
|
17
|
|
Lokelma
|
-
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
8
|
87
|
74
|
|
Crestor*
|
335
|
(5)
|
(6)
|
310
|
(7)
|
(7)
|
337
|
9
|
9
|
296
|
(12)
|
(11)
|
|
Seloken/Toprol-XL*
|
225
|
41
|
38
|
168
|
(25)
|
(25)
|
177
|
6
|
8
|
190
|
7
|
8
|
|
Atacand*
|
50
|
(14)
|
(15)
|
56
|
12
|
14
|
55
|
(1)
|
(1)
|
60
|
8
|
9
|
|
Others
|
71
|
(3)
|
(5)
|
63
|
(11)
|
(8)
|
65
|
4
|
2
|
72
|
13
|
16
|
|
BioPharmaceuticals: total CVRM
|
1,714
|
(2)
|
(3)
|
1,658
|
(3)
|
(3)
|
1,749
|
5
|
6
|
1,785
|
2
|
3
|
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
585
|
(8)
|
(8)
|
585
|
-
|
1
|
613
|
5
|
4
|
712
|
16
|
17
|
|
Pulmicort
|
383
|
(2)
|
(2)
|
333
|
(13)
|
(13)
|
337
|
1
|
3
|
413
|
22
|
23
|
|
Fasenra
|
129
|
3
|
4
|
167
|
29
|
30
|
202
|
21
|
21
|
206
|
2
|
2
|
|
Daliresp/Daxas
|
48
|
(11)
|
(12)
|
56
|
17
|
18
|
53
|
(6)
|
(7)
|
58
|
10
|
10
|
|
Bevespi
|
10
|
-
|
(5)
|
10
|
-
|
2
|
10
|
4
|
8
|
12
|
8
|
5
|
|
Breztri
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
1
|
(74)
|
(73)
|
|
Others
|
128
|
(14)
|
(12)
|
101
|
(21)
|
(23)
|
102
|
1
|
(1)
|
135
|
33
|
38
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,283
|
(6)
|
(6)
|
1,252
|
(2)
|
(2)
|
1,319
|
5
|
6
|
1,537
|
17
|
17
|
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
363
|
(7)
|
(8)
|
393
|
8
|
8
|
374
|
(5)
|
(4)
|
353
|
(6)
|
(6)
|
|
Synagis
|
53
|
(79)
|
(79)
|
96
|
81
|
81
|
146
|
52
|
53
|
63
|
(57)
|
(57)
|
|
Losec/Prilosec
|
76
|
27
|
26
|
68
|
(11)
|
(10)
|
73
|
8
|
9
|
46
|
(38)
|
(38)
|
|
Seroquel XR/IR
|
37
|
(34)
|
(33)
|
32
|
(14)
|
(10)
|
82
|
n/m
|
n/m
|
40
|
(50)
|
(49)
|
|
Others
|
47
|
(65)
|
(64)
|
52
|
11
|
11
|
56
|
8
|
-
|
151
|
n/m
|
n/m
|
|
Total other medicines
|
576
|
(35)
|
(36)
|
641
|
11
|
12
|
731
|
14
|
14
|
653
|
(11)
|
(10)
|
|
Total Product Sales
|
5,465
|
(5)
|
(6)
|
5,718
|
5
|
5
|
6,132
|
7
|
8
|
6,250
|
2
|
3
|
Table 45: Historic Collaboration Revenue (Unreviewed)
|
|
|
H1 2020
|
H1 2019
|
FY 2019
|
FY 2018
|
|
$m
|
$m
|
$m
|
$m
|
||
|
Initial Collaboration Revenue
|
Crestor (Spain)
|
-
|
-
|
-
|
61
|
|
Ongoing Collaboration Revenue
|
Lynparza: regulatory
milestones
|
135
|
60
|
60
|
140
|
|
Lynparza: sales
milestones
|
-
|
-
|
450
|
250
|
|
|
Lynparza/selumetinib: option
payments
|
-
|
-
|
100
|
400
|
|
|
Crestor (Spain)
|
-
|
-
|
39
|
-
|
|
|
Enhertu: profit
share
|
36
|
-
|
-
|
-
|
|
|
Roxadustat: profit share
|
11
|
-
|
-
|
-
|
|
|
Royalty income
|
34
|
32
|
62
|
49
|
|
|
|
Other Collaboration Revenue
|
54
|
39
|
108
|
141
|
|
Total
|
270
|
131
|
819
|
1,041
|
Table 46: Other Operating Income and Expense
(Unreviewed)
The
table below provides an analysis of Reported Other Operating Income
and Expense.
|
|
H1 2020
|
H1 2019
|
FY 2019
|
FY 2018
|
|
$m
|
$m
|
$m
|
$m
|
|
|
Hypertension medicines (ex-US, India and Japan)
|
350
|
-
|
-
|
-
|
|
Inderal, Tenormin,
Seloken and Omepral (Japan)
|
51
|
-
|
-
|
-
|
|
Synagis (US)
|
-
|
515
|
515
|
-
|
|
Losec (ex-China, Japan, US and
Mexico)
|
-
|
-
|
243
|
-
|
|
Seroquel and
Seroquel XR
(US, Canada, Europe and
Russia)
|
-
|
-
|
213
|
-
|
|
Arimidex and
Casodex
(various
countries)
|
-
|
-
|
181
|
-
|
|
Nexium (Europe) and
Vimovo
(ex-US)
|
-
|
-
|
-
|
728
|
|
Seroquel
|
-
|
-
|
-
|
527
|
|
Legal settlement
|
-
|
-
|
-
|
346
|
|
Atacand
|
-
|
-
|
-
|
210
|
|
Anaesthetics
|
-
|
-
|
-
|
172
|
|
Alvesco, Omnaris and Zetonna
|
-
|
-
|
-
|
139
|
|
Other
|
200
|
191
|
389
|
405
|
|
|
|
|
|
|
|
Total
|
601
|
706
|
1,541
|
2,527
|
Shareholder information
|
Announcement of
year to date and third quarter
results
5
November 2020
|
||
|
Announcement of
full year and fourth quarter
results
11
February 2021
|
||
|
|
||
|
Future
dividends will normally be paid as follows:
|
||
|
First
interim:
|
announced
with half-year and second-quarter results and paid in
September
|
|
|
Second
interim:
|
announced
with full-year and fourth-quarter results and paid in
March
|
|
The
record date for the first interim dividend for 2020, payable on 14
September 2020, will be 14 August 2020. The ex-dividend date will
be 13 August 2020.
Trademarks
of the AstraZeneca group of companies appear throughout this
document in italics. Medical publications also appear throughout
the document in italics. AstraZeneca, the AstraZeneca logotype and
the AstraZeneca symbol are all trademarks of the AstraZeneca group
of companies. Trademarks of companies other than AstraZeneca that
appear in this document include Alvesco, Omnaris and Zetonna, trademarks of Covis Pharma;
Atacand, owned by
AstraZeneca or Cheplapharm (depending on geography); Avastin, a trademark of Genentech, Inc.;
Duaklir, Eklira and Tudorza, trademarks of Almirall, S.A.;
Enhertu, a trademark of
Daiichi Sankyo; Losec,
owned by AstraZeneca, Cheplapharm or Taiyo Pharma Co., Ltd
(depending on geography); Seloken, owned by AstraZeneca or Taiyo
Pharma Co., Ltd (depending on geography); Synagis, owned by Arexis AB or AbbVie
Inc. (depending on geography); Vimovo, owned by AstraZeneca or
Grünenthal GmbH (depending on geography).
Information
on or accessible through AstraZeneca’s websites, including
astrazeneca.com,
does not form part of and is not incorporated into this
announcement.
Addresses for correspondence
|
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
|
db@astfinancial.com |
Cautionary statements regarding forward-looking
statements
In
order, among other things, to utilise the 'safe harbour' provisions
of the US Private Securities Litigation Reform Act of 1995,
AstraZeneca (hereafter ‘the Group’) provides the
following cautionary statement:
This
document contains certain forward-looking statements with respect
to the operations, performance and financial condition of the
Group, including, among other things, statements about expected
revenues, margins, earnings per share or other financial or other
measures. Although the Group believes its expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this document and the Group undertakes no
obligation to update these forward-looking statements. The Group
identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause
actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the
Group’s control, include, among other things:
-
the risk of failure
or delay in delivery of pipeline or launch of new
medicines
-
the risk of failure
to meet regulatory or ethical requirements for medicine development
or approval
-
the risk of failure
to obtain, defend and enforce effective intellectual property (IP)
protection and IP challenges by third parties
-
the impact of
competitive pressures including expiry or loss of IP rights, and
generic competition
-
the impact of price
controls and reductions
-
the impact of
economic, regulatory and political pressures
-
the impact of
uncertainty and volatility in relation to the UK’s exit from
the EU
-
the risk of
failures or delays in the quality or execution of the Group’s
commercial strategies
-
the risk of failure
to maintain supply of compliant, quality medicines
-
the risk of illegal
trade in the Group’s medicines
-
the impact of
reliance on third-party goods and services
-
the risk of failure
in information technology, data protection or
cybercrime
-
the risk of failure
of critical processes
-
any expected gains
from productivity initiatives are uncertain
-
the risk of failure
to attract, develop, engage and retain a diverse, talented and
capable workforce
-
the risk of failure
to adhere to applicable laws, rules and regulations
-
the risk of the
safety and efficacy of marketed medicines being
questioned
-
the risk of adverse
outcome of litigation and/or governmental
investigations
-
the risk of failure
to adhere to increasingly stringent anti-bribery and
anti-corruption legislation
-
the risk of failure
to achieve strategic plans or meet targets or
expectations
-
the risk of failure
in financial control or the occurrence of fraud
-
the risk of
unexpected deterioration in the Group’s financial
position
-
and the impact that
the COVID-19 global pandemic may have or continue to have on these
risks, on the Group’s ability to continue to mitigate these
risks, and on the Group’s operations, financial results or
financial condition
Nothing
in this document, or any related presentation/webcast, should be
construed as a profit forecast.
37 Core financial
measures are adjusted to exclude certain items. For more
information on the Reported to Core financial adjustments, please
refer to the introduction to the operating and financial
review.
38 Core financial
measures are adjusted to exclude certain items. For more
information on the Reported to Core financial adjustments, please
refer to the introduction to the operating and financial
review.
58 Quaque die, or once a
day.
59 Bis in die, or twice a
day.
63 A rare autoimmune
condition that causes inflammation of small and medium-sized blood
vessels.
67 White blood cells
gather in the lining of the oesophagus.
79 Conducted by Direction
de la Recherche Clinique et de l’Innovation
L’Assistance Publique - Hôpitaux de Paris (DRCI
AP-HP).
83 The table provides an analysis of
sequential quarterly Product Sales, with actual and CER growth
rates reflecting quarter-on-quarter growth. Due to rounding, the
sum of a number of dollar values and percentages may not agree to
totals. Sequential quarterly Product Sales information included in
the Interim Financial Statements has not been reviewed by
PricewaterhouseCoopers LLP. *Denotes a legacy
medicine.
84 The table below provides an analysis of
sequential quarterly Product Sales, with actual and CER growth
rates reflecting quarter-on-quarter growth. Due to rounding, the
sum of a number of dollar values and percentages may not agree to
totals. The sequential quarterly Product Sales information included
in the Interim Financial Statements has not been reviewed by
PricewaterhouseCoopers LLP. *Denotes a legacy
medicine.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 30 July 2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|